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INTRODUCTION 
In this work, nanoparticles and films consisting of biodegradable comb 
polyesters, poly(vinyl alcohol)-graft-poly(lactide-co-glycolide) (PVA-g-PLGA) 
[1,2], have been investigated as delivery systems for paclitaxel to prevent the 
pathogenesis of postangioplastic restenosis. A more detailed introduction 
dealing with the specific objectives of each research topic is provided in the 
following chapters. This chapter serves as a general introduction explaining the 
basic problems that arise from percutaneous revascularization interventions and 
local drug delivery strategies to reduce restenosis. At the end of the chapter the 
objectives of this work are outlined. 
 
RESTENOSIS: INCIDENCE AND PATHOPYSIOLOGY 
Percutaneous transluminal (coronary) angioplasty, PT(C)A is a very 
useful technique for the treatment of vascular occlusions. Unfortunately, its 
success is often limited by the development of a secondary arterial obstruction, 
also known as restenosis. According to both clinical and angiographic 
definitions, 25 – 35 % of successfully treated atherosclerotic lesions re occlude 
within 3 – 6 months [3], generating increased costs for additional 
revascularization procedures, atherectomy or bypass surgery [4]. Restenosis is 
primarily attributed to neointimal hyperplasia. Balloon angioplasty denudes the 
endothelial layer which normally prevents of blood components from interaction 
with tissue factors and subendothelial parts of the injured vessel wall. When 
such interactions occur, platelet aggregation and the activation of the 
coagulation cascade leads to thrombus formation [5]. This, in turn, stimulates 
the release of cytokines and growth factors, such as platelet-derived growth 
factor (PDGF), basic fibroblast growth factor (bFGF), transforming growth 
factor b (TGFb), thrombin, and angiotensinII [6-10]. Consequently, 
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mononuclear leukocytes enter the arterial wall followed by a transformation to 
macrophages. 
 
Fig. 1: Possible mechanisms of restenosis after PT(C)A and stenting. PTA leads 
to plaque disruptions, and dissections penetrating the media through the 
internal elastic lamina (IEL). Restenosis, caused by arterial remodelling, is 
characterized by shrinkage of the area circumscribed by the external elastic 
lamina (EEL), and intimal hyperplasia. Stenting also enlarges the cross-
sectional area of the vessel wall. Stents prevent vessel shrinkage, however 
intimal hyperplasia can be excessive (adapted from [11]). 
 
These macrophages produce additional vascular smooth muscle cell (VSMC) 
activation elements. Vascular trauma by angioplasty catheter and stents 
application induces necrosis and the activation of VSMC in the media and 
myofibroblasts in the adventitia. Subsequently, cells migrate into the intima, 
where they proliferate and secrete extracellular matrix. VSMC proliferation is 
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due to upregulation and expression of cell division regulating genes such as c-
myc [12,13]. This neointimal tissue then spreads into the lumen [14,15]. 
Collagen deposition and scaring, two processes associated with elastic recoil of 
the vessel wall, dramatically decrease the lumen diameter [16,17]. 
To prevent early elastic vessel recoil and late remodelling of artery rigid 
metallic scaffolds are introduced into the treated segment. Unfortunately, this 
method of intervention can also cause intimal hyperplasia. However, in 
comparison to the angioplasty-induced restenosis, the stent-induced restenosis 
originates from a local tissue reaction to non-biocompatible materials [18-24]. 
Fig. 1 schematically summarizes the morphological consequences of PTA and 
vascular stenting. 
 
RATIONALE FOR LOCAL DRUG DELIVERY 
Despite pharmacologic agents, including antithrombotic, antiplatelet, anti 
proliferative, anti-inflammatory drugs, as well as vasodilators and lipid-lowering 
substances, showed efficient antirestenotic effects in vitro and in animal studies, 
several clinical trial in humans failed [25-30]. The limited efficiency in 
decreasing intimal hyperplasia is often coupled with serious systemic side 
effects, due to inadequate local and high systemic drug concentrations. 
Therefore, interest has focused on the local administration of potentially 
antirestenotic drugs directly to the site of arterial injury following angioplastic 
interventions. This approach has several advantages: 
• High local drug concentrations, 
• Decrease of general drug burden, 
• Decrease of systemic side effects, and 
• Sustained local pharmacodynamic effects by physical or chemical binding 
of the drug to a carrier system. 
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To achieve local drug delivery, different devices have been developed 
combining the technical possibility of delivering the drug with a method of 
angioplasty intervention. These strategies may be classified in balloon catheter 
delivery systems, polymeric or coated stents [30-37], and devices for facilitated 
diffusion. Such devices must meet the following demands: 
• Efficient, homogeny site-specific drug concentrations 
• Little to no additional vascular trauma (proliferative response is 
proportional to the extent of initial arterial injury [38,39] 
• Simple handling 
• Lesion dilatation 
• Maintains distal vascular perfusion if prolonged delivery times are 
required. 
 
DRUG ELUTING STENTS 
A very promising approach to prevent vascular renarrowing after a PTA is 
the implantation of intraluminal stents. Stents are small wire-mesh metal tubes 
which provide a scaffolding to support the damaged arterial wall, thus reducing 
the chance of vessel collapse caused by elastic recoil and vascular remodelling. 
Unfortunately, stent implantation causes intimal hyperplasia. The degree of 
neointima formation is influenced by stent design [40-42], degree of vascular 
injury [38], and stent and coating material [43]. A number of polymers and 
polymer combinations were investigated as potential drug delivery vehicles to 
reduce the incidence of restenosis. These include poly(vinyl 
pyrrolidone)/cellulose esters, poly(vinyl pyrrolidone)/polyurethane, poly 
(methylidene maloleate), polylactide/polyplycolide copolymers, poly (ethylene 
glycol) copolymers, poly( vinyl alcohol) and poly (dimethylsiloxane)-based 
systems [44]. Among the most commonly used methods of coating stents with 
polymers are spray coating (spraying the drug-polymer solution onto the stent) 
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and dip coating (dipping the device in the coating solution and drying upon 
withdrawal) [45]. To minimize platelet activation and reduce thrombus 
formation it is essential that a smooth and defect-free stent coating is achieved. 
 
Approach Drug release Benefits Problems 
Polymeric, non-
biodegradable stents 
Diffusion from 
matrix 
Load and release of 
drugs 
Poor stent stability, 
inflammation 
Polymeric, 
biodegradable stents 
Degradation of 
matrix 
Controlled delivery Inflammation from 
degradation products 
Metallic stents, drug 
coated on surface 
Drug dissolution No issues with 
coatings 
No controlled or sustained 
release 
Chemically attached 
drug onto stent surface 
Cleavage of 
drug-substrate 
bond 
Controlled release Side effects of pro-drug 
Sponge like coatings, 
drugs are absorbed 
Diffusion from 
the matrix 
Load and release of 
drugs Inflammatory reactions 
Biodegradable stent 
coatings 
Degradation of 
the matrix 
Controlled delivery Inflammation from 
degradation products 
Tab. 1: Stent-based methods for local drug delivery (adapted from [46]). 
 
Despite excellent mechanical properties, several polymers exhibit a poor 
biocompatibility characterized by inflammatory and proliferative responses after 
stent implantation [47-49]. To prevent this reactions inhibiting intimal 
hyperplasia and (sub)acute stent thrombosis the drug should be delivered in the 
local area of the stent. Antirestenotic drugs that inhibit thrombus formation (e.g. 
heparin), inflammation (e.g. dexamethasone), and cellular proliferation (e.g. 
sirolimus, paclitaxel), can be incorporated into and released from a polymer 
matrix, or alternatively, can be surrounded by and released through the polymer 
membrane that coats (strut adherent) or spans (strut-spanning) the stent struts. In 
other formulations, the substance is bound directly to the sent surface and can be 
removed by chemical or biological reactions, which cleave drug-substrate bond 
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[46,50]. Other researches have developed stents composed of biodegradable 
polymers in to which the drug is embedded [62,63] to promote optimal healing 
and further reduction of restenosic processes. 
Tab. 1 describes a section of potential ways in which a drug can be 
delivered to the arterial vessel wall. As a result of these intense research efforts, 
several drug eluting stent systems have been developed and are already under 
investigation in clinical trials, as displayed in Tab. 2. 
 
Polymer Drug Trial name Results Ref. 
Poly(ethyl methacrylate)/ n-
butyl metacrylate sirolimus FIM safety [51] 
Poly(ethyl methacrylate)/ n-
butyl metacrylate sirolimus RAVEL 
reduction of 
restenosis [52] 
Poly(ethyl methacrylate)/ n-
butyl metacrylate sirolimus SIRIUS 
ongoing; 
reduction of 
restenosis 
[53,54] 
Phosphorylcholine dexamethasone STRIDE ongoing [55] 
No coating paclitaxel ASPECT reduction of restenosis [56] 
No coating paclitaxel ELUTES reduction of restenosis [57] 
Not specified paclitaxel TAXUS I reduction of restenosis [58] 
Polyacrylate 7-hexanoltaxol SCORE stopped [59] 
No coating heparin COST no reduction [60] 
Phoshorylcholine batimastat BRILLANT stopped [61] 
Tab. 2: Selected clinical studies with polymer coated drug eluting stents 
(adapted from [50]). 
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POROUS BALLOON CATHETER-BASED DRUG DELIVERY 
The rapid washout of infused drug from the target site after administration 
of drug solutions using drug delivery catheters [64] is the main problem of 
intraluminal delivery [34,65,66]. Consequently, researchers have attempted to 
delay drug loss from the vessel wall by incorporating the drug into 
biocompatible and biodegradable polymers formulated as micro- and 
nanoparticles. When infused locally (Fig. 2), the particles may penetrate the 
vessel wall and form a depot, which provide a local, and sustained release of the 
drug in the arterial wall [67-71]. Some researches described a close connection 
between particle size and the penetration into and cellular uptake of particles in 
the vessel wall [70,72]. 
 
Fig. 2: Schematic presentation of the balloon angioplasty combined with 
intraluminal nanoparticle application using porous delivery catheters. (a) 
Catheter is positioned in the artery narrowing. (b) When the balloon is inflated, 
the nanoparticle suspension leak through the micropores and is infused into the 
vessel wall. (c) and (d) show a channelled balloon catheter (SCIMED 
REMEDY™), described in detail by Hong (1993) [86] and Ropiak (1999) [87]. 
(a) (b) (c) (d)
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Polymer Size Drug Technique Ref. 
PLGA 6–8 µm colchicine not specified [68] 
PLGA 90-250 nm dexamethasone emulsion evaporation [76] 
PLGA 5–10 µm hydrocortisone emulsion evaporation [71] 
PLA 600-700 
nm 
dexamethasone 
colchicine 
emulsion 
evaporation/precipitation 
[75] 
PLGA 110–160 
nm 
2-aminochromone emulsion evaporation [77] 
PLGA 60-200 nm 
dexamethasone 
2-aminochromone 
emulsion evaporation [78] 
PLGA 60-140 nm 2-aminochromone emulsion evaporation [74,79] 
PLGA 200 nm probucol emulsion evaporation [80] 
PLA 90-160 nm 
AG-1295 
PTK inhibitor 
spontaneous 
emulsification/solvent 
displacement 
[81,82] 
Albumin not 
specified 
paclitaxel high-pressure 
homogenisation 
[83] 
Per-
fluorcarbon 
250 nm 
doxorubicin 
paclitaxel 
high-pressure 
homogenisation 
[84] 
PLGA 300 nm PDGFβR-AS emulsion evaporation [85] 
Tab. 3: Summary of drug loaded micro – and nanoparticles and applied 
polymeric materials for the prevention of restenosis. 
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Additionally, particle size may even determine the biological response of the 
tissue to the foreign particle material [73,74]. For instance, inflammatory 
reactions with subsequent fibrosis of vascular tissue have been observed when 
applying particles of 5 to 10 µm [68,75].  
Other crucial aspects for a gentle and efficient intraluminal application are 
the infusion pressure and the volume of the infusate, both factors which may 
cause further vascular trauma. Nevertheless, recent studies have reported that the 
particle administration does not aggravate vessel damages caused by vascular 
intervention [71,76]. An overview of colloidal drug delivery vehicles for 
restenosis therapy is provided in Tab. 3. 
 
PACLITAXEL FOR PREVENTION OF RESTENOSIS 
A suitable drug for the treatment of restenosis should be able to inhibit 
several components of the complex process of intimal hyperplasia. Excessive 
neointima formation shows parallels to tumor cell growth making the use of anti 
proliferative agents a reasonable therapeutic approach. Paclitaxel, originally 
isolated from the bark of Taxus brevifolia and commonly used to treat breast 
and ovarian cancer, has been shown to inhibit intimal hyperplasia in vivo 
[88,89]. By binding on the β-subunits of tubulin, paclitaxel promotes the 
formation of numerous decentralized, unorganizsed, and extremely stable 
microtubule bundles, which ultimately leads to inhibition of cell cycle process in 
late G2 and M phase [90,91]. Furthermore, paclitaxel induces long-lasting effects 
in the cell, due to structural alterations of the cytoskeleton. 
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OBJECTIVES OF THIS WORK 
The current work outlines the preparation and characterization of 
nanoparticles (NP) and stent coatings, consisting of the biodegradable comb 
polyester, poly(vinyl alcohol)-graft-poly(lactide-co-glycolide) (PVA-g-PLGA). 
These delivery systems, when loaded with paclitaxel, may be used for the 
prevention of a myointimal response after percutaneous transluminal 
angioplasty, (PTA) which is, as mentioned previously, a factor contributing to 
the development of restenosis. 
The delivery efficiency of free or encapsulated marker substances from 
balloon catheters has already been assessed in several studies. While liquid 
agents showed a very short intramural residence time, the local delivery of 
colloidal drug carriers may help to achieve a sustained and regional release. It is 
known that particle size plays an important role in the penetration and uptake of 
particles into the vessel wall, however, the role of nanoparticle migration and 
deposition has not yet been clearly established. For this reason, the size 
dependent penetration of fluorescently-labelled polystyrene nanoparticles into 
the aorta abdominalis of New Zealand white rabbits was investigated using 
confocal laser scanning microscopy and transmission electron imaging, as 
described in Chapter 2. 
Because high delivery pressures and large volumes of infusate may cause 
severe vascular damage, a further set of experiments (Chapter 3), provided 
more information about the influence of infusion parameters, as well as particle 
concentration with regard to the intramural nanoparticle distribution pattern and 
delivery efficiency. As already described in Chapter 2, model nanoparticles 
consisting of fluorescently-labelled polystyrene, were infused into the aorta 
abdominalis of rabbits. The aim of the study was to define how to modulate the 
infusion parameters for an optimal NP delivery without severe intramural 
dissections. 
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After optimization of the delivery conditions for polystyrene NP, 
investigations were carried out to prepare and characterize NP consisting of 
PVA-g-PLGA comb polyesters in vitro (Chapter 4). These polymers may be 
suitable systems to guarantee a controlled, sustained release of paclitaxel, a 
highly lipophilic, anti proliferative substance. PVA-g-PLGA NP were prepared 
by a modified solvent displacement technique [92]. Paclitaxel release, the 
cellular uptake and, in vitro cytotoxicity of the paclitaxel loaded particles were 
evaluated using rabbit vascular smooth muscle cells (RbVSMC). 
Chapter 5 focuses on paclitaxel loaded films prepared from PVA-g-
PLGA, which, when coated onto a metallic stent, serve as drug release matrices. 
The drug release, degradation, and erosion properties were monitored. 
Additionally, the dispersion state of paclitaxel within the polymer matrices was 
investigated using differential scanning calorimetry (DSC) and wide angle X-ray 
diffraction (WAXD). The Integrity of PVA-g-PLGA coatings after stent 
expansion was visualized using scanning electron microscopy (SEM). A 
summary and prospects for future studies based on the results of this work are 
outlined in the last chapter. 
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SUMMARY 
Restenosis remains the major limitation of percutaneous transluminal 
angioplasty (PTA) and stenting in the treatment of patients with atherosclerotic 
disease. Catheter-based local delivery of pharmacologic agents offers a potential 
therapeutic approach to reducing restenosis and minimizing undesirable 
systemic side effects. However, the intramural retention of liquid agents is low. 
Therefore, to achieve a sustained and regional release of the therapeutic agent it 
must be encapsulated in nanoparticle carrier systems. The purpose of this study 
was to investigate the size dependence of the penetration of nanoparticles after 
local delivery into the vessel wall of the aorta abdominalis of New Zealand 
white rabbits. Two milliliters of a 0.025% fluorescence-labelled polystyrene 
nanoparticle suspension with diameters ranging from 110 to 514 nm were 
infused at 2 atm and at constant PTA pressure of 8 atm into the aorta 
abdominalis. After the infused segments were removed, the location of 
nanoparticles was visualized using confocal laser scanning microscopy and 
transmission electron microscopy. The study demonstrates a size-dependent 
nanoparticle penetration into the intact vessel wall. While nanoparticles of about 
100 and 200 nm were deposited in the inner regions of the vessel wall, 514-nm 
nanoparticles accumulated primarily at the luminal surface of the aorta. The 
observations confirm that size plays a critical role in the distribution of particles 
in the arterial vessel wall. It is additionally influenced by the formation of 
pressure-induced infusion channels, as well as by the existence of anatomic 
barriers, such as plaques, at the luminal surface of the aorta or the connective 
elastic tissue. 
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INTRODUCTION 
Restenosis is defined as a reobstruction of an artery following arterial 
interventions, such as balloon angioplasty, atherectomy, or stenting of an 
atherosclerotic plaque, and is characterized by intimal hyperplasia and vessel 
remodeling [1-4]. Intimal growth results from vascular smooth muscle cell 
(VSMC) migration and proliferation into the media [5] followed by the 
formation of extracellular matrix [6]. Currently, different routes of drug 
administration in restenosis therapy are under investigation. The proliferation of 
VSMC, the cause of restenosis development, could be inhibited by the 
application of radioactive [7] and drug eluting stents [8,9]. Another method to 
reduce VSMC growth and neointimal formation is the local administration of a 
drug solution using drug delivery catheters [10]; however, the delivery 
efficiency and intramural retention time of infused agents remains rather low 
[11,12]. Therefore, researchers have developed colloidal drug carrier systems 
from biodegradable polymers that may provide a local release and sustained 
retention of the drug in the arterial wall [13-17]. 
Recent studies have indicated that particle size plays an important role in 
the penetration and cellular uptake of particles into the vessel wall [16,18]. 
Furthermore, particle size may even determine the biological response of the 
tissue to the foreign particle material [19,20]. For instance, inflammatory 
reactions with subsequent fibrosis of vascular tissue have been found when 
applying particles with a size of 5 to 10 µm [13,21]. 
Guzman et al [22] observed that fluorescent-labelled particles of 165 nm 
that were first deposited in the luminal, medial, and adventitial layers of the 
artery were found afterward in only the adventitia. They concluded that the 
adventitial layer acts as a reservoir for particles and eluted drugs, which then 
subsequently diffuse in the direction of the media. A discontinuous particle 
distribution has been also found by Rome et al [18]. They showed that different 
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types of particles, ranging between 90 to 500 nm in size, tended to accumulate in 
the outer wall layers but not in the media. These authors suggested that the 
particles reach the adventitia via the vasa vasorum, but not directly by 
penetrating the wall. Song et al [23,24] explained the fluorescence activity of 
rhodamine B-loaded poly(D,L-lactide-co-glycolide (PLG) nanoparticles in the 
media of a dog carotid artery by the possibility of inward migration of 
nanoparticles from the adsorption site at the intraluminal surface. On the one 
hand, these findings suggest that particles smaller than 300 nm are well suited as 
an effective intraluminal drug delivery system. On the other hand, the migration 
and deposition behavior of nanoparticles in the tissue is not yet clearly 
established. 
The present study concentrates on the size-dependent penetration of 
nanoparticles into the aorta abdominalis of New Zealand white rabbits. In 
contrast to other authors, we used fluorescence-labelled instead of fluorescence-
loaded particles to avoid any unintentional dye release that would prevent the 
exact determination of the particle distribution by confocal laser scanning 
microscopy (CLSM). Our investigations have shown that the particle migration 
through the wall tissue is in fact size dependent and, furthermore, is strongly 
influenced by the existence of atherosclerotic plaques at the luminal surface of 
the aorta, as well as by the formation of channel-like diffusion paths induced by 
pressurized infusion. 
 
MATERIALS AND METHODS 
Local nanoparticle delivery 
All animal experiments followed the “Principles of Laboratory Animal 
Care” (National Institutes of Health publication #85-23, revised 1985) and were 
approved by an external review committee for laboratory animal care. Male 
New Zealand white rabbits (3.5-4 kg) were sacrificed using a mixture of 
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embutramide, mebenzonium iodide, and tetracaine hydrochloride. The aorta 
abdominalis was exposed in-situ (averaging 20-30 mm in length). For 
angioplasty and local delivery, a channelled balloon catheter (SCIMED 
REMEDY, Boston Scientific, Natick, MA) was placed in the aorta abdominalis. 
The delivery device has been described in detail by Hong et al [25]. Briefly, it is 
a 3-lumen over-the-wire catheter with separate ports for balloon dilation and 
local drug delivery. The balloon carries 18 channels, with 1 group of 30-µm 
diameter pores per channel. The catheter shaft is 3.4 French. During this study, 
we used a balloon length of 20 mm and a diameter of 2.5 mm. 
Yellow-green labelled polystyrene nanoparticles of 110, 217, and 514 nm 
in diameter (Fluoresbrite plain microspheres YG, Polyscience Inc, Warrington, 
PA) were suspended in water. Two milliliters of each suspension (0.025% 
(wt/vol) in water) were infused at a constant pressure of 2 atm and at a constant 
balloon pressure of 8 atm. A control experiment was performed by infusion of 
0.9% sodium chloride solution. After the infusion experiments, arterial segments 
were removed and fixed in formalin solution (4% vol/vol) for CLSM or 
glutaraldehyde (2.7% vol/vol) in phosphate buffered saline (PBS) 0.1M, pH 7 
for transmission electron microscopy. 
 
Confocal laser scanning microscopy 
Arterial segments were frozen in isopentane on ice and embedded in 
Tissue Freezing Medium (Jung, Germany). Cross-sections of 20-µm thickness 
were cut using a Frigocut 2700 cryo microtome (Reichert-Jung, Germany) and 
mounted on SuperFrost plus (Menzel-Glaeser, Germany) glass slides. They were 
counterstained with 4 6-diamidino-2-phenylindole (DAPI) (1 µg/mL) 
(Molecular Probes, Leiden, The Netherlands) solution in PBS for 30 minutes 
under light exclusion and embedded in PBS/glycerol (2:1 vol/vol). Localization 
of fluorescence-labelled nanoparticles was performed using a CLSM (Axiovert, 
Zeiss CLSM 501, Jena, Germany) equipped with a Zeiss Neofluor 40*/1.3 
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objective. Excitation wavelengths were 364 nm (long-pass filter [LP] 385 nm) 
for DAPI and 488 nm (LP 505 nm) for the yellow-green labelled nanoparticles. 
All confocal images were acquired with the same settings with respect to laser 
intensity, filter block, and detector gain. 
 
Transmission electron microscopy 
The fixed blood vessels were rinsed 3 times with 0.15M PBS, pH 7 for 1 
hour each and postfixed for 75 minutes in 2% osmium tetroxide. Dehydration 
was accomplished in a series of mixtures of water with component A (a water-
soluble aliphatic polyepoxide) of the Durcupan ACM water-soluble embedding 
medium (Fluka, Germany) as follows: 
• 50% component A with 50% water for 30 minutes 
• 70% component A with 30% water for 45 minutes 
• 90% component A with 10% water for 45 minutes 
• 100% component A for 90 minutes 
 
The dehydrated tissue was then placed in a polymerization mixture of the 
components A through D (components B and C are hardeners; component D is 
the plasticizer) according to the manufacturer’s protocol and left overnight in a 
refrigerator for final mixing and embedding. Polymerization was performed in a 
freshly prepared mixture of the above composition for 4 days at 42°C. 
 
Ultrathin sections, about 50-nm thick, were obtained using a Leica 
Ultracut UCT ultramicrotome and a diamond knife (Leica Microsystems, 
Bensheim, Germany). The sections were collected on copper grids covered by a 
thin layer of colodium and carbon. Final staining of the sections included 
treatment with uranylacetate for 15 minutes and with lead citrate for 9 minutes. 
Microscopic examinations were carried out with a JEM 3010 transmission 
electron microscope (Jeol Electron Microscope, Japan) operated at 300 kV, 
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equipped with a MegaScan CCD (charge-coupled device) camera (2048 x 2048 
pixel). 
 
RESULTS AND DISCUSSION 
Cross-sections from the infusion experiments without fluorescent probes 
exhibited no or negligible green autofluorescence at standard confocal settings 
(Fig. 1A). Green autofluorescent emissions of arterial elastin and collagen 
structures can be well distinguished from the blue stained nuclei of smooth 
muscle, endothelial, and adventitial cells, as well as from the nanoparticles. The 
observed cross-sections of the arterial segments subjected to intramural 
nanoparticle infusion using a perforated balloon catheter did not show any 
severe disruptions of the vessel wall. 
Confocal laser scanning analyses revealed a size-dependent penetration 
depth of the nanoparticles in the non-atherosclerotic arterial wall at constant 
infusion pressure. As displayed in Fig. 1B, the 514-nm nanoparticles were 
observed to accumulate preferentially at the luminal surface of the aorta. Only a 
negligible number of particles was detected in the inner parts of the vessel wall. 
With decreasing diameter, the penetration capability of the particles increased, 
as shown in the case of 217-nm particles in Fig. 1C and 1D, and 110-nm 
particles in Fig. 2A. High fluorescent activity in deeper cell layers of the vessel 
wall, especially in the latter case, indicates that nanoparticles of 110 nm easily 
penetrate through the arterial wall. Sometimes a tendency toward cluster 
formations was observed on the luminal surface. Furthermore, it seems quite 
obvious that the particle distribution between the luminal site and the adventitial 
layer is not continuous. This is documented by systematic observations and is 
not based on sectioning artefacts. On the other hand, discontinuous particle 
concentrations crossing the artery wall may be caused by differences in the 
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accessibility, the transmission properties, and the holding behavior of the 
different vessel wall layers. 
 
Fig. 1: CLSM analysis of the nanoparticle distribution in the vessel wall of the 
aorta abdominalis of New Zealand white rabbits: nuclei (blue) stained with 
DAPI, catheter-delivered yellow-green labelled polystyrene nanoparticles 
(green). P, L, M, and A indicate the atherosclerotic plaque, lumen, media, and 
adventitia. (A) Balloon-dilated segment of aorta abdominalis: control 
experiment without nanoparticle infusion. (B) Confocal image: accumulation of 
514-nm particles on the luminal surface of the aorta. (C and D) Confocal 
images: distribution of 217-nm particles in the aorta abdominalis; optical 
sections were taken from the inner medial (C) and the adventitial part (D) of the 
vessel wall layers (2.87 µm each layer). 
 
While the CLSM images provide an overview of the delivery 
characteristics of the nanoparticles across the blood vessel, the precise 
localization of the particles within a particular tissue layer needs a higher 
resolution achieved by using transmission electron microscopy. Fig. 3A to 3F 
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are transmission electron micrographs of stained ultra-thin sections from the 
endothelial region (Fig. 3A-3C) and the media (Fig. 3D-3F) for the 3 particle 
sizes used: 514, 217, and 110 nm. In the inner region the endothelial cells show 
mechanical distortion due to the catheter intervention. In the medial layer typical 
views of the glycogen strands are revealed. The size dependency of particle 
deposition is proved by Fig. 3A to 3F, with only the small-sized particles 
reaching the inner wall regions in considerable amounts. 
 
Fig. 2: Confocal images: distribution of 110-nm particles in a non-
atherosclerotic vessel segment (A) in comparison to an atherosclerotic segment 
(B). 
 
Observations of atherosclerotic arteries showed that plaques on the 
endothelial cell layer are able to inhibit even the penetration of the 110-nm 
nanoparticles (Fig. 2B). The plaque consists of collagen, fibrin, smooth muscle 
cells, foam cells, and macrophages, which form a rather solid layer on the inner 
vessel surface. Hence, they may act as a strong barrier to particle penetration. 
Preliminary experiments using nanoparticles as small as 57 nm in diameter have 
led to the same result (data not shown): hindrance of transportation into the 
vessel wall by a barrier of extended plaque formation. 
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Fig. 3: Transmission electron micrographs of the accumulation of 110-, 217-, 
and 514-nm particles in the endothelial layer (A, B, E) and in the media (B, D, 
F) of the aorta abdominalis of New Zealand white rabbits (lumen left). Segment 
D provides clear proof of how the elastica tissue acts as a diffusion barrier. 
 
Fig. 4: Scanning electron micrographs of the infusion holes in a REMEDY 
balloon catheter showing one group comprising 18 channels (a) and 2 holes at 
higher magnification (b). Some holes remained filled with organic material after 
use. 
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The elastic connective tissue can also function as a strong transport barrier 
for the nanoparticles, as Fig. 3D illustrates. The 217-nm particles are strung like 
pearls alongside the interface to the elastica externa; the particles were neither 
able to penetrate nor to permeate the elastic tissue. 
The CLSM image in Fig. 1C is part of a gallery of 7 optical sections 
(2.87 µm each section). In one of the upper sections of this sequence, particle 
deposition in the endothelium and the adventitia was observed, as was particle 
deposition along a radial channel-like trace connecting the inner and outer 
regions of the vessel, as Fig. 1D shows. It is suggested that such traces originate 
from the directed stream of nanoparticles ejected under pressure through the 
holes of the perforated balloon catheter. The size and the configuration of the 
infusion holes in the catheter wall may, thus, influence the distribution 
characteristics of the nanoparticles in the blood vessel strongly. Fig. 4 shows the 
typical arrangement and shape of the holes in the REMEDY catheter used in this 
study. The 25-µm holes are arranged in groups of 18, of which 6 such groups are 
distributed over the circumference in a repetitive manner at a distance along the 
catheter axis of approximately 5 mm. The hole diameter and the width of a 
diffusion channel in Fig. 1C are in the same order of magnification. 
The feasibility of local drug delivery with a perforated balloon catheter 
for the prevention of restenosis was first demonstrated by Wolinski and Thung 
[10]. However, the intramural delivery efficiency and the retention time of 
liquid agents was low [10-13]. To overcome this drawback, microparticles have 
been evaluated as potential drug delivery vehicles [13-17]. The predominant 
sites of microparticle deposition were found to be the adventitial vasa vasorum, 
the periadventitial microvasculature, and along intimal disruptions [16,17] but 
usually not the target tissue, the media. One important aspect of these carrier 
systems is the effect of particle size on penetration behavior and cellular uptake 
by the vessel wall [18]. In addition to that, particle size is associated with 
biological response of the tissue to foreign biomaterials [19,20]. While 
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inflammatory reactions with subsequent fibrosis is a typical response of vascular 
tissue to particulate delivery systems ranging in size between 5 and 10 µm 
[13,21], nanoparticles usually cause little or no focal inflammation. 
Guzman et al. [22] found fluorescence-loaded PLGA particles of 90 to 
250 nm predominantly at the lumen surface of the vessel wall and in the 
adventitial layer. Only a few particles were observed in the media [22]. Rome et 
al [18] suggested that particles smaller than 500 nm, which had mainly 
accumulated within the intimal and adventitial layers, reach the media via vasa 
vasora of the artery. Song et al [23] reported fluorescence activity of 100 to 200 
nm rhodamin B-loaded PLGA nanoparticles in the media of a dog carotid artery, 
which was explained by the possible migration of particles from adsorption sites 
at the luminal surface. 
Our study adds an additional aspect to the understanding of particle 
migration. The channel-like deposition patterns observed after application of 
217-nm particles seem to be caused by the pressure-induced particle stream 
from the catheter pores through the intima and media into the adventitial layer. 
To achieve a similar effect using larger particles, the infusion pressure needs to 
be increased considerably. This could have detrimental consequences to the 
wound healing process of the injured vessel wall. When smaller nanoparticles 
(≤200 nm) are applied, a lower infusion pressure is necessary; thus, the 
formation of extended vessel lesions is prevented. The most favorable pressure 
level should provide sufficient nanoparticle deposition in the vessel wall and, at 
the same time, avoid unrecoverable vessel irritations. According to our 
experience, pressure levels of about 2 to 4 atm are efficient and atraumatic in 
this model. 
Possible anatomic barriers to any particle transportation through the wall 
tissue are the intact internal and external elastic laminae. Moreover, the presence 
of atherosclerotic plaques on the inner luminal surface strongly influences the 
particle penetration into the arterial wall, as our results have shown. Independent 
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of their size, nanoparticles are deterred at the surface of the dense plaque layer 
and are unable to penetrate the vessel wall. This observation points to additional 
complications of drug delivery strategies in restenosis. 
 
CONCLUSIONS 
Because of their size, nanoparticles are suitable as drug carrier systems for 
localized application of therapeutic agents in restenosis therapy. In the present 
study, the local administration of polystyrene nanoparticles using a perforated 
balloon catheter could be successfully visualized by CLSM and transmission 
electron microscopy. It was demonstrated that nanoparticles can penetrate the 
non-atherosclerotic arterial vessel wall and that the penetration depth can be 
adjusted by varying the particle size. Direct evidence is provided for the 
existence of very local penetration paths of the nanoparticles as result of the 
pressure-directed particle stream during balloon infusion. 
Apart from anatomic barriers — including the intact endothelial layer, as 
well as intact internal and external elastic laminae — atherosclerotic plaques 
seemed to prevent nanoparticulate drug carriers from penetrating the vessel wall 
in the absence of dissections. Further experiments on the effect of infusion 
pressure, suspension volume, and nanoparticle concentration are under way to 
clarify in detail the suitability of nanoparticles as effective intraluminar drug 
delivery systems for the prevention of restenosis after balloon angioplasty. 
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SUMMARY 
Catheter-based local delivery of drug loaded nanoparticles agents offers a 
potential therapeutic approach to reducing restenosis. However, high delivery 
pressures and large volumes of infusates may cause severe vascular damage and 
increase intimal thickening. Therefore, we investigated the penetration pattern 
and vessel wall integrity of fluorescence-labelled nanoparticles (217 nm in 
diameter) into the non-atherosclerotic aorta abdominalis of New Zealand white 
rabbits in dependence of the volume (2.5 and 5 ml) and concentration (0.5 and 1 
mg/ml) of the nanoparticle suspension, as well as the infusion pressure (2 and 4 
atm) using a channelled balloon catheter (SCIMED REMEDY ™ model RC 
20/2.5). The location and penetration characteristics of nanoparticles in the 
arterial vessel wall were visualized using confocal laser scanning microscopy 
(CLSM) and transmission electron microscopy (TEM). 
Catheter design and infusion pressure form a radial particle stream 
through intima and media into the adventitial layer of the aorta abdominalis. 
Infusion pressures of 4 atm in combination with high particle concentrations 
lead to effective nanoparticle delivery without severe vessel wall disruptions. 
Endothelium of the treated vessel segments was slightly affected during catheter 
insertion showing partly denudation of the innermost cell layer. TEM 
micrographs underlines transport functional properties of the vasa vasorum 
inside the vessel wall. 
Consequently, local delivery efficiency of nanoparticulate carriers is 
critically affected by infusion pressure, and concentration of carrier suspensions. 
These factors need to be taken into consideration for the design of in vivo 
experiments. 
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INTRODUCTION 
Interventional procedures such as percutaneous transluminal balloon 
angioplasty (PTA) or stenting are most frequently accompanied by arterial 
vessel re-obstruction also known as restenosis. This process is characterized by 
intimal hyperplasia and vessel remodelling [1-3]. The neointimal formation 
results from vascular smooth muscle cell (VSMC) migration and proliferation 
into the media [4] followed by the formation of a new extra cellular matrix [5]. 
Apart from the application of drug eluting stents for local delivery [6,7], 
the development of balloon catheter delivery systems [8] allows the infusion of 
drug-loaded micro- [9-12] or nano-carriers [13-16] to provide a local and 
sustained drug release at the site of angioplasty. This technique ensures higher 
drug concentrations than systemic administration [17]. Although recent studies 
have demonstrated that particles < 300 nm easily penetrate the vessel wall and 
appear, therefore, to be promising carrier systems in restenosis therapy [15,18], 
their successful application strongly depends on the particular infusion 
conditions. For instance, the infusion pressure and the volume of the infusate are 
crucial parameters that may cause severe vascular damage and enhanced intimal 
thickening [19]. 
The present study describes the effects of particle suspension volume, 
particle concentration, and infusion pressure on the intramural distribution of 
fluorescence-labelled polystyrene nanoparticles into the non-atherosclerotic 
vessel wall of the aorta abdominalis in New Zealand white rabbits using a 
channelled balloon catheter. The aim of this study was to determine how to 
modulate the infusion parameters for an optimal nanoparticle delivery without 
severe intramural dissections. Our investigations have shown that the particle 
migration through the wall tissue is pressure dependent and is characterized by 
channel-like deposition patterns corresponding to the porous balloon catheter 
design. The increase of nanoparticle suspension volume could not improve the 
intramural particle concentration. 
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MATERIALS AND METHODS 
Local delivery catheter 
The delivery device, a channelled balloon catheter (SCIMED 
REMEDY™ model RC 20/2.5, lot 3377794, Boston Scientific, Natick, MA), 
has been described in detail by Hong [20]. Briefly, it is a 3-lumen over-the-wire 
catheter with separate ports for balloon dilation and local drug delivery, which 
allows separation of the high inflation pressure for angioplasty from the low 
pressure desirable for local nanoparticle delivery. The balloon carries 18 
channels, with one group of 30-µm diameter pores per channel in a spiral pattern 
for local delivery. In order to further reduce vessel wall injuries the particle 
suspension is allowed to leak through the micro pores rather than be propelled 
by jet streams. The catheter shaft is 3.4 French. Balloons used in this study were 
20 mm in length and 2.5 mm in diameter. 
 
In-situ catheterization and local delivery of fluorescence-labelled 
nanoparticles 
The investigation conformed to the guidelines for the care and use of 
laboratory animals published by the US National Institute of Health (“Principles 
of Laboratory Animal Care”, NIH publication No. 85-23, revised 1985) and 
were approved by an external review committee for laboratory animal care. 
Four non-atherosclerotic male New Zealand white rabbits weighing 3.5 to 
4 kg were sacrificed using a mixture of embutramide, mebenzonium iodide, and 
tetracaine hydrochloride. To perform angioplasty and local nanoparticle 
delivery, the aorta abdominalis was exposed in situ (averaging 20-30 mm in 
length) and cut longitudinally. The catheter was placed above the aortic 
bifurcation. The location, quantity, and penetration depth of 217 nm yellow-
green labelled polystyrene nanoparticles were evaluated in relationship to 
particle concentration, injection pressure, and suspension volume of Fluoresbrite 
™ plain microspheres YG suspended in water (Polyscience Inc, Warrington, 
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PA). The use of fluorescence-labelled instead of fluorescence-loaded 
nanoparticles avoids any unintentional dye release that would prevent the exact 
determination of particle distribution by CLSM. The experimental set-up is 
described in Tab. 1. 
 
Animal no. Vessel segment 
Infusion 
Pressure     
[atm] 
Suspension 
Volume        
[ml] 
Particle 
Concentration     
[mg/ml] 
1 distal 2 2 0.25 
1 proximal 4 2 0.25 
2 distal 2 2.5 0.25 
2 proximal 2 5 0.25 
3 distal 2 2 0.5 
3 proximal 2 2 1.0 
4 proximal  no infusion  
Tab. 1: Experimental setup for nanoparticle infusion at different settings 
(Particle size: 217 nm). 
 
In all experiments the angioplasty balloon was inflated and maintained at 
a dilating pressure of 8 atm until the entire nanoparticle suspension was infused. 
A non-treated vessel segment served as negative control. Immediately after the 
delivery procedure the treated and control vessel segments were excised and 
fixed in a formalin solution (4% v/v) for CLSM studies or glutaraldehyde (2.7% 
v/v) in phosphate buffered saline (PBS) 0.1M, pH 7 for electron microscopy. 
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Confocal laser scanning microscopy (CLSM) 
Arterial segments, frozen in cooled isopentane, were embedded in Tissue 
Freezing Medium (Jung, Germany). Cross-sections of 20-µm thickness were cut 
using a Frigocut 2700 cryo-microtome (Reichert-Jung, Germany) and mounted 
on SuperFrost plus (Menzel-Glaeser, Germany) glass slides. They were 
counterstained with 46-diamidino-2-phenylindole (DAPI, 1 µg/mL) (Molecular 
Probes, Leiden, The Netherlands) solution in PBS for 30 minutes under light 
exclusion and embedded in PBS/glycerol (2:1 v/v). Localization of 
fluorescence-labelled nanoparticles was performed using a CLSM (Axiovert, 
Zeiss CLSM 501, Jena, Germany) equipped with a Zeiss Neofluor 40*/1.3 
objective. Excitation wavelengths were 364 nm (long-pass filter [LP] 385 nm) 
for DAPI and 488 nm (LP 505 nm) for the yellow-green labelled nanoparticles. 
All confocal images were acquired with the same settings with respect to laser 
intensity, filter block, and detector gain. 
 
Transmission electron microscopy (TEM) 
The fixed blood vessels were rinsed 3 times with 0.15M PBS, pH 7, for 1 
hour each and postfixed for 75 minutes using 2% osmium tetroxide solution. 
Small parts of the vessels were embedded for ultramicrotomy using Durcupan 
ACM (Fluka, Switzerland), a four component water-soluble embedding 
medium. After dehydration of the tissues in a water-soluble aliphatic 
polyepoxide as described elsewhere [18], the dehydrated tissue was placed in a 
polymerization mixture according to the manufacturer’s protocol and left 
overnight at 4 °C for final mixing and embedding. Polymerization was 
performed in a freshly prepared mixture of the above composition for 4 days at 
42°C. 
Ultrathin sections, approximately 50 nm thick, were obtained using a 
Leica Ultracut UCT microtome and a diamond knife (Leica Microsystems, 
Germany). The sections were collected on copper grids covered with a 
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supporting thin collodium/carbon film. Final staining of the sections included 
the treatment with uranyl acetate for 15 minutes and with lead citrate for 9 
minutes. Microscopic examinations were carried out in a JEM 3010 
transmission electron microscope (Jeol, Japan), equipped with a 2k x 2k Slow-
scan CCD camera and a LaB6 cathode, operated at 300 kV. 
 
Scanning electron microscopy (SEM) 
The inner surface morphology of the blood vessels after catheterization 
was controlled using both TEM, as well as SEM observations. The 
glutaraldehyde fixed specimens were dehydrated using a critical-point drying 
apparatus Polaron E3000 (Bio-Rad Microscience) after stepwise replacement of 
the water by acetone, which is than substituted by carbon dioxide. Finally, the 
dried specimens were coated with a thin gold evaporation layer to prevent 
charging. Sample characterization was performed by scanning electron 
microscopy using a CamScan Series 4 (CamScan, USA) at 20 kV acceleration 
voltage. 
 
Semi-quantitative analyses of penetration depth and fluorescent intensity 
Selective particle distributions and tissue autofluorescence complicated 
the determination of a defined front line of fluorescent nanoparticles. 
Consequently, the penetration depth was measured semi-quantitatively and 
graded on a scale from 1 to 3 according to Fram [21]. Briefly, grade 1 described 
penetration into the inner one-third of the vessel wall, grade 2 into the inner two-
third, and grade 3 into the outer one-third of the vessel wall of the aorta 
abdominalis. The fluorescence intensity was graded in the same manner on a 
scale from 1 to 3, corresponding to light, moderate, and intense fluorescence. 
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RESULTS AND DISCUSSION 
As a result of the catheter insertion into the aorta abdominalis and its 
removal, as well as catheter dilatation during ballooning, there is always the risk 
of mechanical injury to the endothelial layer. Generally, the affected vessel 
segments showed little or no damaging of the endothelium (Fig. 1a and 1c), 
although in some selected cases we observed some disturbances of the 
endothelial layer (Fig. 1b and 1d). The cross-sections of the treated arteries 
usually did not show any severe vessel wall disruptions. In CLSM images, the 
light green autofluorescence, at an excitation wavelength of 488 nm, as seen in 
cross-sections of control experiments without nanoparticle infusion was well 
distinguishable from the blue DAPI stained nuclei of smooth muscle, 
endothelial, and adventitial cells, as well as from the nanoparticles themselves 
(Fig. 2a). 
One method to enhance drug delivery efficiency is the use of smaller 
drug-loaded nanoparticles. Further possibilities include the increase of 
nanoparticle suspension volume, particle concentration, or infusion pressure. 
Our results of semi-quantitative analyses of penetration depth and fluorescence 
intensity after delivery of 217 nm-sized fluorescence-labelled nanoparticles in 
dependence of the latter parameters are shown in Tab. 2. 
The increase of suspension volume from 2.5 to 5 ml did not lead to a 
higher fluorescence activity in several analysed cross-sections from treated 
vessel segments as derived from a comparison of Fig. 2b and c. Only light 
fluorescence in the intimal and medial layer could be observed. The capacity of 
the vessel tissue appears to be low for large volumes of drug solutions or drug 
carrier suspensions. 
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Fig. 1: SEM images (a, b) and TEM images (c, d) of the endothelial layer of the 
aorta abdominalis. After balloon dilatation and nanoparticle infusion the 
endothelium appears sporadically intact (a, c). In Figures b and d the 
endothelial layer appears to have been completely removed. 
 
In contrast, a remarkable increase in nanoparticle uptake was observed as 
a consequence of an increased infusion pressure from 2 to 4 atm (Fig. 3a and b). 
In a number of cases, the nanoparticles poured in a funnel-shaped manner 
through the intimal layer into the medial tissue as shown by CLSM in Fig. 3b, as 
well as by the TEM images in Fig. 3c. Occasionally, the formation of a particle 
cloud with high fluorescence activity extending up to the adventitial region of 
the vessel wall could be observed (Fig. 3b). At the interface between the arterial 
tissue and the lumen, the particles seemed to stream back into the luminal area 
and build particle clusters. The channel-like particle streams at the infusion site 
have a diameter of about 25 µm which correlates with the pore diameter of the 
balloon catheter. 
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Parameter Value Penetration depth 
Fluorescence 
intensity 
Infusion Pressure [atm] 2 / 4 2 / 3 2 / 3 
Particle Concentration 
[mg/ml] 0.5 / 1 3 / 3 2 / 3 
Suspension Volume [ml] 2.5 / 5 2 / 2 2 / 1 
Tab. 2: Infusion characteristics: Semi quantitative analysis of penetration depth 
and fluorescence intensity. Penetration depth is graded into 1 = inner one-third, 
2 = inner two-thirds, 3 = outer one-third of the vessel wall.  Intensity of 
fluorescence was graded into 1 = light, 2 = moderate, and 3 = intense 
fluorescence. 
 
Apart from the depicted penetration characteristics of the nanoparticles, 
which tend to cross the successive layers of the vessel wall preferably along 
infusion-induced diffusion channels, other possible transport pathways are 
revealed in Fig. 4. The TEM micrographs show cross-sections ( Fig. 4a and c) 
and longitudinal sections (Fig. 4b) of the vasa vasora with and without 
nanoparticle incorporations. These examples are evidence for the transport 
functional properties of the vasa vasorum. 
Moreover, in Fig. 5 an extensive fluorescence signal over all vessel wall 
layers is shown with a substantially higher intensity at an increased particle 
concentration of 1 mg/ml (Fig. 5b) compared to concentrations of 0.5 mg/ml 
(Fig. 5a). 
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Fig. 2: CLSM analysis of the nanoparticle distribution in the vessel wall of the 
aorta abdominalis of New Zealand white rabbits: Nuclei (blue) stained with 
DAPI, catheter-delivered yellow-green labeled polystyrene nanoparticles 
(green). L, M, and A indicate the lumen, media, and adventitia. (a) Balloon-
dilated segment of aorta abdominalis: Control experiment without nanoparticle 
infusion. (b) Infusion of 2.5 ml nanoparticle suspension (0.25 mg/ml, 2 atm) in 
comparison to (c) 5 ml suspension. 
 
 
Fig. 3: CLSM images of the nanoparticle distribution in the vessel wall after 
infusion at (a) 2 atm and (b) 4 atm. (b) shows a radial channel-like particle 
influx into the vessel wall with a “cloudy” particle accumulation spreading over 
the intimal medial and adventitial layer. (c) transmission electron micrograph of 
funnel shaped particle deposition in the medial layer. 
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Fig. 4: Transmission electron micrographs of a vasa vasorum (a - c) with 
nanoparticle deposition displayed in (b) and (c). 
 
Fig. 5: CLSM images of arterial vessel segments infused with nanoparticle 
suspensions of (a) 0.5 mg particles per ml and (b) 1.0 mg particles per ml. 
 
Although the microporous design of balloon catheters was effective for 
the local infusion of anti-restenotic drugs [19], the intramural drug delivery is 
considered to be associated with additional vessel trauma, such as endothelial 
abrasion, disruptions of intima or elastica lamina, and dissections of the arterial 
vessel wall. Recent studies have described a direct relationship between the 
damage of arterial vessels and infusion pressure of local delivery during 
percutaneous transluminal angioplasty [22,23]. Wolinsky et al. found that the 
infused dye entered such crevices and that the disruptions were indeed induced 
by the angioplasty procedure [24]. The injuries in the arterial vessel wall may 
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also have been caused by high pressure jet streams from the application pores of 
the perforated balloon catheter [25,26]. Furthermore, vessel wall disruptions and 
intimal hyperplasia were more prominent at higher inflation pressures during 
balloon angioplasty [27], as well as at higher infusion pressures during catheter-
based nanoparticle application [28]. 
Despite some occasional endothelial abrasion caused by catheter 
intervention, the cross-sections of the present study did not reveal any noticeable 
dissections of the vessel wall at infusion pressures of 2 and 4 atm or at higher 
fluid volumes. These observations are in agreement with the findings of Gunn, 
who showed that local delivery of oligonucleotides for antisense therapy caused 
no evident vessel wall disruptions at infusion pressures between 1 and 6 atm 
[29]. 
Whereas some researchers did not observe any significant differences in 
the delivery efficiency of drug solutions [30] or fluorescent-labelled 
microparticles [11] at increasing infusion pressures, Fram and co-workers have 
shown that the penetration depth of horseradish peroxidase was directly related 
to the infusion pressure [21]. Our results also demonstrate an enhancement of 
particle deposition at the delivery site with increasing pressure. On the other 
hand, however, in the present study the evaluation of the depth of vessel wall 
penetration revealed no differences at infusion pressures of 2 or 4 atm. The 
fluorescence-labelled nanoparticles were visible in all vessel wall layers 
arranged in a funnel-like manner without vascular damage. Data from a non-
atherosclerotic rabbit carotid artery model using a channelled balloon catheter 
indicated jet injuries which were detected in areas where the application pores 
directly contacted the vessel wall [26]. We suppose that the described deposition 
pattern is the result of the observed infusion-induced particle stream from the 
catheter pores. 
It has become evident that fluid volumes of more than 2 ml do not 
effectively increase the drug delivery efficiency simply because of the low 
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capacity of the treated vessel wall segment. Instead, high fluid volumes may 
increase the traumatic side effects during local drug delivery with porous 
balloons considerably, as reported by Herdeg [26]. Consequently, it is 
reasonable to increase the drug delivery efficiency by using higher concentrated 
drug or drug-carrier solutions, rather than larger volumes. 
Limitations of the present study are the lack of quantitative information 
about the absolute particle mass delivered to the vessel wall which is an 
important aspect in the validation of the biological effect of drug loaded 
particles. Also, when using non-atherosclerotic vessel segments one has to be 
aware that atherosclerotic plaques may reduce nanoparticle delivery. Finally, 
this study has not taken any delayed vascular damage, such as neointimal 
thickening and the associated increase in the SMC proliferation activity, into 
account. 
 
CONCLUSIONS 
We observed a channel-like particle penetration into the vessel wall of the 
aorta abdominalis as a function of catheter design; however, we were able to 
determine that the leaking effect of the channelled balloon seemed to prevent 
traumatic jet streams to the greatest possible extent. Consequently, the increase 
of the infusion pressure from 2 or 4 atm promoted nanoparticle delivery without 
causing severe vessel wall ruptures. The local delivery efficiency of particulate 
drug carriers depended on different factors such as catheter design, particle size, 
infusion pressure, and concentration of drug carriers. Whereas an increased 
particle concentration consequently led to a higher suspension viscosity, 
increased infusion pressures were required for the delivery of the viscous 
suspensions, which may cause severe damages of the vessel wall architecture. 
Therefore, it is extremely important to define well-balanced parameters for 
particle size, infusion pressure, particle concentration and administrated volume 
specific to the catheter system used. Nevertheless, nanoparticulate drug and gene 
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carriers based on biodegradable polymers offer a promising approach for the 
treatment of restenosis after angioplasty. 
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SUMMARY 
Restenosis artery after percutaneous transluminal angioplasty (PTA) and 
stenting remains a challenge for the treatment of patients with atherosclerotic 
diseases. Catheter-based local delivery of biodegradable nanoparticles (NP) with 
sustained release characteristics, potentially represents a therapeutic approach to 
reduce the restenosis. Paclitaxel loaded NP (0, 0.5, 1, 2 % (w/w)) consisting of 
poly(vinyl alcohol)-graft-poly(lactide-co-glycolide) (PVA-g-PLGA) with 
varying PLGA chain length as well as poly(lactide-co-glycolide) (PLGA), were 
prepared by a solvent evaporation technique. NP of < 180 nm in diameter 
characterised by photon correlation spectroscopy (PCS), scanning electron 
microscopy (SEM), and atomic force microscopy (AFM) are spherical and show 
smooth surfaces. Yields typically range from 80 to 95 % with encapsulation 
efficiencies between 77 and 87 % (theoretical loading 2%) The extent of initial 
in vitro paclitaxel release (drug burst) was affected by the PVA-g-PLGA 
composition. A decreased PLGA chain length increased drug release rates. 
Blank nanoparticles from PVA300-g-PLGA(30) and PVA300-g-PLGA(15) 
showed excellent biocompatibility in rabbit vascular smooth muscle cells 
(RbVSMC) at polymer concentrations of 0.37 mg/ml. Paclitaxel-loaded NP have 
decreased the cell viability more effectively than the free drug. Confocal laser 
scanning microscopy of RbVSMC confirmed the cellular uptake of 
nanoparticles composed of fluorescently labelled PVA300-g-PLGA(15) loaded 
with Oregon green labelled paclitaxel. Cells showed a clearly increased 
fluorescence activity with a co-localisation of paclitaxel and polymer 
nanoparticles after 6 hours. These results demonstrates that PVA300-g-PLGA 
comb polyesters are suitable for sustained paclitaxel release and may have 
potential for catheter based delivery to prevent restenosis after PTA. 
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INTRODUCTION 
The recurrent luminal narrowing of an artery (restenosis) as a 
consequence of excessive intimal hyperplasia limits the long-term success of 
arterial interventions such as percutaneous transluminal angioplasty (PTA) and 
stenting in the treatment of patients with atherosclerotic disease. Restenosis is 
characterised by vascular smooth muscle cell (VSMC) migration and 
proliferation into the media [1] followed by extracellular matrix formation [2]. 
To inhibit VSMC proliferation, drugs must be delivered at high concentrations 
for a prolonged period of time. Catheter-based local delivery of pharmacologic 
agents offers a potential approach to reduce restenosis, minimizing undesirable 
systemic side effects. However, recent studies demonstrated that the delivery 
efficiency and intramural retention of directly infused drug solutions remains 
rather low [3,4]. Thus, colloidal drug carriers based on biodegradable polymers 
have been developed to provide local drug release and sustained retention of 
drug in the arterial wall. Recent studies have demonstrated that nanoparticles 
can be delivered more efficiently to the arterial tissue than microparticles [5-7]. 
Numerous drugs were investigated for the inhibition of intimal thickening [8]. A 
promising approach to inhibit restenosis is the controlled release of paclitaxel 
[9,10]. Paclitaxel, a very potent anti proliferative drug which binds to the β-
subunits of tubulin, promotes the formation of extremely stable and non-
functional microtubule bundles. As a result, cell replication is blocked in late G2 
and M phase of the cell cycle [11]. Due to the poor solubility of paclitaxel in 
water, the solvent displacement technique [12], which is widely used for 
encapsulation of lipophilic drugs, is an attractive method to form nanoparticles. 
Several different types of biodegradable polymers such as polylactide (PLA) 
[13,14], poly (lactide-co-glycolide) (PLGA) [15,16], or polycaprolactone (PCL) 
[17] have been used to formulate sustained release nanoparticles. In the present 
study, nanoparticles from biodegradable comb polyesters [18,19] were prepared 
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using the solvent displacement method. These brush-like grafted polyesters 
consists of a hydrophilic polymer backbone, PVA, onto which hydrophobic 
PLGA is grafted. This polymer structure offers various possibilities to modify 
drug release kinetics. Firstly, the water uptake and swelling properties of the 
matrix can be varied by changing the hydrophilic part of the polymer. Or 
secondly, the degradation and release behavior can be modified by grafting 
PLGA with different chain length onto the backbone [20]. 
Our study was carried out to characterize nanoparticles from PVA-g-
PLGA comb polyesters with regard to their applicability as vascular paclitaxel 
delivery system by investigating drug release, in vitro cytotoxicity, and cellular 
uptake behavior. 
 
MATERIALS AND METHODS 
Materials 
Linear PLGA 50:50 (RG 503H, Mw 28, 000 g/mol was supplied by 
Boehringer Ingelheim (Germany). Paclitaxel (Genexol) was kindly provided 
by Sam Yang Corp.(Seoul, Korea). Radio-labelled paclitaxel (paclitaxel-[2-
benzoyl ring-UL- 14C]) was obtained from Sigma (Sigma Chemicals, Germany). 
Oregon Green labelled Paclitaxel and 7-methoxy-coumarin-3-carbonyl azide for 
fluorescence labelling of PVA300-g-PLGA was purchased from Molecular 
Probes (Leiden, Netherlands). Poloxamer 188 (Pluronic F 68) was supplied by 
BASF (Parsippany, NJ)). The liquid scintillation cocktail was obtained from 
Packard BioScience (Ultima Gold LS cocktail, Groningen, Netherlands). All 
other chemicals of analytical grade were purchased from Sigma (St. Louis, MO). 
 
Poly((polyvinyl alcohol)-g-(D,L-lactide-co-glycolide)) 
Synthesis and characterization were described by Breitenbach et al. [18]. 
Briefly, comb polyesters were synthesized by a stannous octoate catalyzed ring-
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opening polymerization of lactide and glycolide (1:1) in the presence of the 
backbone poly(vinyl alcohol) (PVA; MW 15 kg/mol, polymerization degree 300, 
hydrolysis degree 88%) under anhydrous conditions. The polymers used for 
nanoparticle preparation were described in table 1. The following nomenclature 
will be used to specify the polymers: PVA300-g-PLGA(XX). The number in 
parenthesis refers to the mass ratio of branched PLGA, which is grafted (g) onto 
hydrophilic backbone, compared to the PVA. 
For cellular nanoparticle uptake studies PVA300-g-PLGA(15) was 
fluorescently labelled as follows: 7-methoxy-coumarin-3-carbonyl azide was 
added to a solution of the polymer in N-methyl-pyrrolidone. The reaction 
mixture was stirred at 80 °C for 4 hours. After cooling to room temperature, the 
solution was poured into demineralized water and the precipitate was collected 
by filtration. The product was washed several times and dried in a vacuum 
chamber at room temperature for 6 days. The theoretical degree of substitution 
was 9.6 %. Infrared and 1H-NMR spectroscopy confirmed the coupling of the 
fluorescent marker to the polymer with an excitation wavelength of 340 nm and 
an emission wavelength of 430 nm as determined by fluorescence spectroscopy. 
 
Nanoparticle preparation 
Nanoparticles were formed by a modified solvent displacement technique, 
described in detail elsewhere [21]. Briefly, polymer (20 mg) and paclitaxel (0, 
0.5, 1, 2 mg) were co-dissolved in 2 ml acetone. The resulting solution was 
added at constant flow rate of 10.0 ml/min to 10 ml of a stirred (500 rpm) 
aqueous phase of filtrated (0.2 µm, Schleicher & Schuel, Germany) and double-
distilled water containing 0.1 % (m/m) poloxamer 188 (Pluronic F68) using a 
syringe with injection needle (Sterican 0.6 × 25 mm; B Braun, Melsungen, 
Germany). For the release study, nanoparticles were directly prepared in the 
release medium composed of a phosphate buffered (0.05M, I = 0.01, pH 7.4) 
poloxamer 188 solution. The resulting colloidal suspension was stirred for 2 h 
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under reduced pressure to remove residual organic solvent. The nanoparticle 
suspension was stored at 4 °C until use. For determination of drug loading 
efficiency and in vitro drug release, 14C-labelled and unlabelled paclitaxel were 
mixed at a mass ratio of 1 / 250. The nanoparticle yield was determined 
gravimetrically after preparation, and additionally, after the passage through a 
channelled balloon delivery catheter (SCIMED REMEDY ™ model RC 20/2.5, 
lot 3377794, Boston Scientific, Natick, MA). The catheter used carries 18 
channels, with 1 group of 30-µm diameter pores per channel for infusion of drug 
solutions, or particle suspensions into the vessel wall [22]. All measurements 
were performed in triplicate. 
Nanoparticles for cellular uptake studies consisted of a mixture 
fluorescently labelled PVA300-g-PLGA(15) (20%) and unlabelled PVA300-g-
PLGA(15) (80%) loaded with 0.1 % Oregon green labelled paclitaxel. 
 
Nanoparticle characterization 
Particle size measurement 
For measurement of average size and size distribution of the nanoparticle 
suspensions by photon correlation spectroscopy (PCS) (Zetasizer 4/AZ 110; 
Malvern Instruments, UK), each sample was diluted with filtrated and distilled 
water to a nanoparticle concentration of 0.5 mg/ml to avoid multiscattering 
events. The photon correlation spectroscopy software V 1.26 was used to 
calculate mean diameter and width of fitted gaussian distribution. Moreover, the 
NP size was determined after passage through the channelled balloon catheter. 
Each measurement was performed in triplicate. 
 
Scanning electron microscopy (SEM) 
The morphology of nanoparticles was characterized by SEM using a 
Hitachi S-4100 microscope (Hitachi, Germany). A drop of the nanoparticle 
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suspension (2 mg/ml) was placed on a glass cover slide and dried under vacuum 
for 12 h. After that, the slides were mounted on aluminium pins using double-
sided adhesive tape. Prior to microscopical examination the samples were coated 
with a gold layer under vacuum for 30 seconds (Edwards Auto 306, Edwards, 
Germany). 
 
Atomic force microscopy (AFM) 
A drop of the nanoparticle suspension was directly placed on a silicon 
chip. Atomic force microscopy was performed with a Digital Nanoscope IV 
Bioscope (Veeco Instruments, Santa Barbara, CA) as described elsewhere [23]. 
The vibration damped microscope was equipped with pyramidal Si3N4 tips 
(NCH-W, Veeco Instruments, Santa Barbara, CA) on a cantilever with a length 
of 125 µm, a resonance frequency of about 220 kHz and a nominal force 
constant of 36N/m. To avoid damage of the sample surface all measurements 
were performed in the tapping mode. The scan speed was proportional to the 
scan size with a scan frequency from 0.5 to 1.5 Hz. Images were obtained by 
displaying amplitude, height and phase signal of the cantilever in the trace 
direction recorded simultaneously. 
 
Determination of encapsulation efficiency (EE) 
After centrifugation of 1 ml of the nanoparticle suspension (10 minutes at 
10 000 rpm) the clear supernatants were removed and the sediments were 
dissolved in acetone before mixing with 5 ml of scintillation cocktail. The 
activity of radio labelled paclitaxel in supernatants and residues was quantified 
by liquid scintillation counting (LSC) (Tri-Carb 2100TR, Packard BioScience, 
Germany). The encapsulation efficiency was calculated by comparing the actual 
and theoretical loading in consideration of the 14C-paclitaxel / paclitaxel ratio. 
Each sample was measured in quadruplicate. 
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In vitro release of paclitaxel 
One ml of the nanoparticle suspension in 1.5 ml Eppendorf cups 
(Eppendorf, Germany) was placed in an incubator at 37°C. At predetermined 
time intervals, the buffer was withdrawn after centrifugation and replaced by 
fresh buffer. The amount of drug released and the encapsulation efficiency were 
determined in quadruplicate as described above. 
 
In-vitro cell culture studies 
Rabbit vascular smooth muscle cell (RbVSMC) culture 
The cells were isolated from abdominal aortas of New Zealand white rabbits 
[24] and cultured in DMEM (Dulbecco’s modified Eagle medium, Sigma-
Aldrich, Germany) supplemented with 2 mM glutamine (Sigma-Aldrich, 
Germany) and 10% fetal calf serum (Gibco, Germany) at 37°C, 95% r.h. and 
8.5% CO2. Vascular smooth muscle origin was confirmed by 
immunocytochemical staining with monoclonal antibodies against smooth 
muscle alpha actin (Progen Ind., Australia). Assays were always performed in 
the exponential growth phase of the cells. Absence of mycoplasmas was assured 
using the DAPI (46-diamidino-2-phenylindole) staining method (Molecular 
Probes, Leiden, The Netherlands). 
 
In-vitro cytotoxicity using MTT Assay 
In-vitro cytotoxicity of blank, paclitaxel loaded nanoparticles from 
PVA300-g-PLGA(15) and PVA300-g-PLGA(30), and free paclitaxel were 
investigated using the primary RbVSMC culture. Nanoparticles were prepared 
under aseptic conditions. Paclitaxel was dissolved in 96% ethanol. To obtain 
different test concentrations, several dilutions of paclitaxel stock solution and 
nanoparticle suspensions were prepared with DMEM culture medium. Ethanol 
amounts used for dilution showed no influence on the cell viability during the 
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experiments. RbVSMC were seeded into 96-well microtiter plates (Nunclon™, 
Nunc, Germany) at a density of 5000 cells/well. After 24 h the culture medium 
was replaced with different dilutions of the stock solutions. After an incubation 
period of 24 h the culture medium was replaced with fresh, drug-, and 
nanoparticles- free culture medium. After an additional incubation time of 48 h 
the viability of the cells was evaluated by the MTT assay (n = 7). MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) (Sigma-Aldrich, 
Germany) was dissolved in phosphate buffered saline at 5 mg/ml and 20 µl were 
added to each well reaching a final concentration of 0.5 mg MTT/ml. After an 
incubation time of 4 h unreacted dye was removed by aspiration, the purple 
formazan product was dissolved in 200 µl/well dimethyl sulfoxide and 
quantitated by a plate reader (Titertek Plus MS 212, ICN, Germany) at 
wavelengths of 570 and 690 nm. Poly(ethylene imine) 750 kDa (BASF, 
Germany) at 1 mg/ml in DMEM was used as a positive control and 
poly(ethylene) 600 (Merck, Germany) at 1mg/ml in DMEM as a negative 
control. 
 
Cellular nanoparticle uptake study using confocal laser scanning microscopy 
(CLSM) 
For CLSM experiments a Zeiss Axiovert 100 M microscope coupled to a 
Zeiss LSM 510 scan module was used. Cells were seeded at a density of 20, 000 
cells per well in 8 well chamber slides (Lab Tek, Nunc, Germany). After 24 h 
medium was removed and cells were incubated with 50 µl particle suspension 
(2mg/ml, theoretical paclitaxel loading: 0.1 % (w/w)). After 6 h NP containing 
medium was removed again and cells were washed three times with 
phosphorous buffered saline (PBS). Fixation of cells was performed by 
incubation with 400 µl paraformaldehyde solution 3 % in PBS for 20 minutes. 
For exitation of the coumarine derivative attached to the polymer PVA300-g-
PLGA(15) an Enterprise UV laser with a wavelength of 364 nm was used. 
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Exitation of Oregon Green attached to paclitaxel was performed by using an 
argon laser with a wavelength of 488 nm. Images were recorded in multitracking 
mode using longpass filters of 385 nm and 505nm. 
 
RESULTS AND DISCUSSION 
NP characterization 
The solvent evaporation method appears to be particularly suitable for the 
preparation of PVA-g-PLGA nanoparticles [21]. The mechanism of particle 
formation thought to occur according to “diffusion-stranding” process found in 
spontaneous emulsification also designated as Marangoni – effect [25]. The 
morphology of nanoparticles prepared by the solvent displacement technique is 
exemplarily shown for NP from PVA300-g-PLGA in Fig. 1 and 2. The surface of 
spherical NP appeared to be smooth and without pores, similar to NP from PLA, 
or PLGA [16,26]. The mean particle size ranged between 140 and 170 nm (Fig. 
3) as confirmed by SEM. Apparently, the encapsulation of paclitaxel did not 
affect the nanoparticle size, or polydispersity indices (0.1 to 0.17) suggesting 
uniform, and monomodal size distributions. Particle yields were in the range of 
80 to 94 % (Fig. 4), and were comparable to recently published results [27]. The 
passage of nanoparticles through the channelled balloon catheter did not 
influence the particle size or yield, as shown in Fig. 3 and Fig. 4. The 
encapsulation efficiency (EE) at a theoretical loading of 2 % ranged from 77 % 
for PVA-g-PLGA (10) NP to 87 % for PVA-g-PLGA(30) NP. In comparison 
PLGA NP showed a EE of 80% equal to NP from PVA-g-PLGA(15). 
In contrast to other researchers who visualized cellular NP uptake with 
fluorescence loaded nanoparticles [28,29], we prepared NP using 7-methoxy-
coumarin-3-aminocarbonyl–conjugated PVA300-g-PLGA(15). The use of 
fluorescently labelled instead of fluorescence-loaded particles avoids any 
unintentional dye release that would prevent the exact determination of the 
particle distribution by confocal laser scanning microscopy (CLSM).  
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Fig. 1: Scanning electron micrographs of nanoparticles prepared from (A), (B) 
PVA300-g-PLGA(30), (C) PVA300-g-PLGA(15), and (D) fluorescence labelled 
PVA300-g-PLGA(15) loaded with 0.5 % paclitaxel. 
 
Fig. 2: Atomic force micrographs showing surface properties of polymer 
nanoparticles prepared from (A) PVA300-g-PLGA(15), and (B) fluorescence 
labelled PVA300-g-PLGA(15). Each single image has a edge length of 5 µm. 
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Fig. 3: Size of nanoparticles (NP) prepared from PVA300-g-PLGA determined by 
photon correlation spectroscopy. PVA300-g-PLGA(30)* = NP batch for size 
determination after passage through a channelled balloon delivery catheter 
(SCIMED REMEDY™). All measurements were performed in triplicate. 
Fig.4: Yield of nanoparticles prepared from three different PVA300-g-PLGA 
comb polyesters. It is expressed as the ratio between the polymer mass in the 
suspension and the theoretical amount. PVA300-g-PLGA(30)* = NP batch for 
yield determination after passage through a channelled balloon delivery 
catheter (SCIMED REMEDY ™). All measurements were performed in 
triplicate.  
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Fluorescently labelled paclitaxel loaded nanoparticles thus obtained for cellular 
uptake studies have a particle size of 118.4 nm ± 7.3 nm with a polydispersity 
index of 0.1 ± 0.024 (Fig. 3), and additionally, show the same shape and surface 
characteristics (Fig. 1 and 2) as unlabeled nanoparticles. 
 
 
In vitro drug release 
The influence of polymer composition on the cumulative drug release of 
paclitaxel loaded NP is shown in Fig. 5. The early release phase is dominated by 
an initial drug burst. In the case of PVA300-g-PLGA(10) nearly 80 % of the 
encapsulated paclitaxel was released during the first day. An increased chain 
length resulted in a substantial decrease of burst rates as observed for PVA300-g-
PLGA(15) (56 %) and PVA300-g-PLGA(30) NP (38%). PLGA NP exhibited the 
lowest burst release of ca. 35 %. The following release phase of all NP species 
was characterized by a slow but continuous profile over a time period of 22 
days. Other authors observed comparable release behavior with regard to PLGA 
NP [26,27]. The paclitaxel release exhibited a biphasic release pattern which 
was characterized by an initial drug burst during the first 24 h, followed by a 
slower release phase.  
The burst release of hydrophobic paclitaxel from the nanoparticles is 
possibly due to the influence of the hydrophilic backbone and the PLGA chain 
length of the polymers. The lower the PLGA chain length the lower the 
lipophilicity of the polymer, and furthermore, the lower the solubility of 
paclitaxel in the polymer, resulting in an increased amount of free paclitaxel and 
a decreased EE compared to the other comb polyesters, and especially to PLGA 
[19]. 
Another important aspect is the presence of surfactant acting as stabilizing 
agent for the NP suspension. While the hydrophobic drug containing organic 
solution was added to the surfactant containing water phase, the paclitaxel may 
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accumulate in the hydrophobic domains of the surfactant molecules. When the 
NP solidify in the aqueous phase and surfactant molecules attach to the 
hydrophobic NP surface, the drug is not able to diffuse back into the solid core 
of the nanoparticles [30]. Dissolution and diffusion procedures of the drug, 
which was adsorbed onto the NP surface, could lead to an initial drug burst, 
while the slower and continuous release phase may be attributed to the diffusion 
of the drug localized in the NP core [31]. 
Fig. 5: Effect of the polymer composition on the in vitro paclitaxel release from 
nanoparticles loaded with 2 % paclitaxel / 14C-paclitaxel (mass ratio 250:1). 
(Encapsulation efficiencies ranges from 77 to 87 %). The drug released was 
determined by liquid scintillation counting (LSC). Each sample was measured in 
quadruplicate. 
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following, and substantial sustained drug release rate is to obtain a constant drug 
level to prevent excessive VSMC proliferation persistently. Previous results of 
in-vitro cell culture studies showed a paclitaxel induced decrease in cell viability 
of human VSMC at a drug concentration range of 0.1 to 10 µmol/L, which is 
potentially favorable for local delivery. An increase in cell apoptosis was 
observed at higher drug levels (50 to 100 µmol/L) [32]. The intimal VSMC that 
follows vascular injury during angioplasty procedures reaches a maximum at 10 
to 14 days and ends upon re-endothelization of the traumatized vessel segment. 
But due to a relatively short residence time of paclitaxel in VSMC, the 
application of free drug containing solutions could be less efficient to inhibit 
restenosis, as demonstrated for bovine VSMC [33], which underlines the need of 
sustained-release dosage forms of anti proliferative drugs. By specific variation 
of PVA-g-PLGA polymer composition we were able to adjust the initial drug 
dose, which is released immediately after the infusion of the nanoparticle 
suspension into the vessel wall, and subsequently, a delayed drug liberation 
provides a persistent effect on VSMC proliferation. 
 
In vitro cytotoxicity 
The MTT test serves as an assay for proliferation and cell viability by 
measuring the metabolic activity of cells. Metabolically active cells are able to 
convert the yellow water-soluble tetrazolium salt (3-(4,5 dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) to a water-insoluble dark blue formazan by 
reductive cleavage of the tetrazolium ring. For in vitro cytotoxicity all 
components, which were used for nanoparticle preparation, were tested. The 
suspension stabilizer poloxamer 188 did not decrease the viability of RbVSMC 
up to concentrations of 10 mg/ml (data not shown). Pistel et al. (2001) have 
already demonstrated the good biocompatibility of PVA-g-PLGA polymer using 
the extraction method [19]. The non-toxic character of unloaded nanoparticles 
prepared from PVA300-g-PLGA(30) and PVA300-g-PLGA (15) was confirmed up 
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to NP concentration of ca. 370 µg/ml, as shown in (Fig. 6). By contrast 
paclitaxel loaded PVA-g-PLGA nanoparticles showed a concentration 
dependent viability of RbVSMC. An increase of nanoparticle concentration 
from 3 to more than 300 µg/ml was accompanied by a reduction in cell viability 
of about 30 %. Furthermore, and this effect highlights the rationale for the 
encapsulation of anti proliferative drugs for local vascular delivery, at higher 
drug levels free paclitaxel was less toxic compared to drug-loaded nanoparticles, 
probably due to a higher cellular uptake of nanoparticles (Fig. 6). Hence, 
nanoparticles formed a depot from which the paclitaxel is released continuously 
after the initial burst. 
Fig. 6: Cytotoxicity of free paclitaxel (Ptx) (star symbol), blank nanoparticles 
(filled symbols) and Ptx-loaded nanoparticles (open symbols) (theoretical 
loading 2 %) from PVA300-g-PLGA(30) (open and filled squares) and PVA300-g-
PLGA(15) (open and filled circles) by means of MTT assay. 
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Nanoparticle uptake into RbVSMC 
Confocal laser scanning microscopy of VSMC exposed to fluorescence 
labelled nanoparticles (blue fluorescence) loaded with 0.1 % of Oregon green 
labelled paclitaxel (green fluorescence) demonstrated an increased fluorescence 
activity in the cells after an incubation period of 6 h (Fig. 7). Based on results 
from the in vitro cytotoxicity test, fluorecently labelled paclitaxel in the chosen 
concentration did not affect cell viability of VSMC negatively during NP uptake 
experiments. The image shown is a z-section through the center of the cells and 
confirms that the fluorescence observed is the result of nanoparticle localization 
inside the cells and not on the membrane surface. The co-localization of NP and 
paclitaxel fluorescence appeared in yellow fluorescence as a consequence of NP 
internalization. 
Various processes, such as phagocytosis [34], receptor mediated 
endocytosis, or fluid phase pinocytosis [33] are hypothesized for cellular uptake 
of particulate drug carriers in smooth muscle cells. In fact phagocytosis is 
generally associated with the uptake of large particles (> 500 nm) and not with 
NP of about 100 – 200 nm, which was confirmed by testing the phagocytic 
activity of human VSMC in the presence of NP in vitro [29]. 
As shown by Fig. 7, the size and localization the intracellular vesicles 
suggests the NP are probably located in the endosomal/lysosomal compartment 
surrounding the nucleus [33,35]. The appearance of diffuse green and blue 
fluorescence indicates a subsequent NP escape into the cytoplasm, as 
hypothesized by Panyam et al. (2002) [35]. As a result of uptake inhibition at 
low temperatures and saturation kinetics during incubation with poly(ethylene 
oxide)-poly(lactide-co-glycolide) NP, Suh et al. (1998) proposed that the uptake 
is through adsorptive pinocytosis [33]. In contrast it was also demonstrated that 
in parts PLGA NP without any specific ligands were internalized nonspecifically 
through clathrin vesicles which are known to be involved in active receptor 
mediated endocytosis [35]. 
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However, further investigations with regard to the mechanism of 
nanoparticle uptake and the kinetics of drug uptake and retention in the VSMC 
will be helpful to establish the efficiency of PVA-g-PLGA nanoparticles for the 
prevention of excessive proliferation of VSMC after balloon angioplasty. 
 
Fig. 7: CLSM images demonstrating intracellular nanoparticle (118.4 nm ± 7.3; 
PI 0.1 ± 0.024) distribution in RbVSMC after 6 hours of incubation. (A) 
Distribution of Oregon Green labelled paclitaxel (green), and (B) of from 7-
methoxy-coumarin-3-carbonyl azide labelled PVA300-g-PLGA(15) (blue) loaded 
with 0.1 % fluorescently labelled paclitaxel. (C) Differential interference 
contrast image showing the outline of the cells. (D) Overlay of (A) and (B) 
showing the co-localization of nanoparticles and paclitaxel. Each image shown 
is a z-section through the center of the cells supporting location of nanoparticles 
inside the cells. Scale bar represents 20 µm. 
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CONCLUSIONS 
This study describes the formulation of biodegradable nanoparticles 
(< 180 nm) using the solvent displacement technique for catheter-based local 
intraluminal drug delivery. PVA-g-PLGA comb polyesters are suitable 
biodegradable polymers for the nanoencapsulation of paclitaxel leading to 
encapsulation efficiencies of 87 %. By varying the composition of PVA-g-
PLGA polymers the release kinetics can be adapted to the clinical requirements 
of drug delivery for prevention of restenosis. We have further demonstrated that 
unloaded PVA-g-PLGA nanoparticles are non toxic to RbVSMC and capable of 
sustained intracellular delivery of paclitaxel. Paclitaxel loaded nanoparticles 
decrease the cell viability of RbVSMC in-vitro more effective than the free 
drug. Confocal laser scanning microscopy confirmed the uptake of paclitaxel-
loaded nanoparticles. Because of their variability, PVA-g-PLGA polymers are 
well suitable candidates to encapsulate also hydrophilic agents, such as 
oligonucleotides, peptides or proteins [19]. 
These findings support the rationale for the design of colloidal drug 
delivery systems based on biodegradable nanoparticles from poly(vinyl 
alcohol)-g-lactide-co-glycolide), which offer attractive features for the 
prevention of restenosis after angioplasty.  
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SUMMERY 
Although substantial progress in catheter and stent design have improved 
success of percutaneous transluminal angioplasty (PTA) of atherosclerotic 
disease, the incidence of restenosis caused by in-stent neointimal hyperplasia 
remains a serious problem. Therefore, drug-eluting stents were developed for the 
site-specific delivery of anti-restenotic agents. We investigated biodegradable 
polyesters, namely poly(lactic-co-glycolic acid) (PLGA) and different 
poly(vinyl alcohol)-graft-poly(lactic-co-glycolic acid) (PVA-g-PLGA) as 
paclitaxel-eluting stent coating materials. In our studies PLGA showed sigmoid 
release behavior, paclitaxel release from PVA-g-PLGA films, in contrast, was 
continuous over 40 days without drug burst. Wide angle X-ray diffraction 
confirmed that paclitaxel is dissolved in the polymer matrix. Paclitaxel 
crystallisation becomes observable at drug loadings ≥ 10 %. The effect of drug 
loading on polymer degradation was studied in films prepared from PVA300-g-
PLGA(30) with paclitaxel loadings of 5 and 15% over a time period of 6 weeks. 
The results suggest a more heterogonous mechanism of degradation including 
surface and bulk erosion. Drug release rates from the PVA-g-PLGA films were 
improved resulting in more continuous release profiles. A model stent (Jostent 
peripheral) coated with Parylene N, a poly(p-xylylene) (PPX) derivate, was 
covered with a second layer of PVA300-g-PLGA(15), and PVA300-g-PLGA(30) 
by using air brush method. Morphology of coated stents, and film integrity after 
expansion from 3.12 mm to 5 mm was investigated by scanning electron 
microscopy (SEM). Except of some minor cracks, devices resisted mechanical 
stress during stent expansion. 
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INTRODUCTION 
All forms of percutaneous vascular interventions such as balloon 
angioplasty or stenting cause injury on the vessel leading to vessel recoil and 
neointima formation [1-4]. Stenting prevents vessel recoil and remodelling [5], 
but enhances intimal hyperplasia [6]. This neointima formation, which is 
responsible for in-stent restenosis, remains an important clinical problem in the 
treatment of vascular occlusions. Stent material and surface properties are key 
determents in the formation of in-stent restenosis. Commonly used bare metal 
stents offer excellent mechanical stability, but often increase the incidence of 
thrombosis, fibromuscular proliferation and formation of restenosis. Polymer 
coatings have been suggested to improve stent biocompatibility. However, 
several biodegradable and non-biodegradable polymers have shown conflicting 
results provoking a severe tissue response [7]. Therefore, the formulation of 
stents which are loaded with anti-proliferative drugs, such as paclitaxel [8;9], or 
sirolimus [10] is an attractive approach for inhibition of neointimal hyperplasia. 
Currently available drug-eluting stents systems (DESS) base on surfaces 
coated with drug containing polymer matrices, ceramic, or carbon coatings, as 
well as drugs directly applied to the stent surface. Randomised clinical trials 
[11], e.g. SIRIUS, RAVEL (Sirolimus-eluting Cypher-stent) [12], or TAXUS 
I-VI (Paclitaxel-eluting stent) [13] have demonstrated their ability to reduce the 
incidence of restenosis following stenting. 
Besides controlled and site-specific drug elution, the polymer matrix 
should have good mechanical properties in terms of flexibility and long lasting 
adherence to the stent surface at the required size when the device is deployed. 
Due to its elasticity, biostability and biocompatibility, poly(p-xylylene) (PPX) 
[14;15] ensures stent endothelization, and prevents acute vessel thrombosis, as 
well as foreign-body reactions after stent implantation. PPX derivates, such as 
Parylene C and Parylene N are already recognized as Class VI polymers by the 
FDA. 
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Here we study paclitaxel-loaded polymeric film coatings based on poly 
(vinyl alcohol)-graft-poly(lactide-co-glycolide) (PVA-g-PLGA) comb 
polyesters. PVA-g-PLGA consist of a hydrophilic backbone, polyvinyl alcohol 
(PVA), which was grafted with PLGA chains. This non-toxic polymer structure 
offers various possibilities to modify drug release kinetics. Firstly, the water 
uptake and swelling properties of the matrix could be varied by changing the 
hydrophilic part of the polymer. Or, secondly, the degradation and release 
behavior may be assessable by grafting PLGA with different chain lengths onto 
the backbone [16;17]. Paclitaxel loaded films were studied with respect on 
polymer degradation and drug release behavior. To prove the mechanical 
integrity of the PVA-g-PLGA matrix, Jostent peripheral (JOMED, Germany) 
stents were coated twice, as illustrated schematically in Fig. 1. Firstly, stents 
were completely covered with Parylene N, using the chemical vapour deposition 
method (CVD) [18]. In a second step a solution of PVA-g-PLGA in chloroform 
is sprayed onto the stent struts by using air brush method forming a polymer 
matrix which covers only the outer, vessel wall directed surface. This prevents 
undesirable drug release into the blood stream, that may lead to systemic side 
effects in contrast to coatings formed by device dipping, which covers the total 
device surface. 
 
MATERIALS AND METHODS 
Materials 
Linear PLGA 50:50 (RG 503H, Mw 28, 000 g/mol) was purchased from 
Boehringer Ingelheim (Germany). Paclitaxel (Genexol) has been kindly 
provided by Sam Yang Corp.(Seoul, Korea). Radio labelled paclitaxel 
(paclitaxel-[2-benzoyl ring-UL- 14C]) was obtained from Sigma (Sigma 
Chemicals, Germany). Dimethylacetaminde (DMAc) was supplied from Fluka 
(Germany). Liquid scintillation cocktail was obtained from Packard BioScience 
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(Ultima Gold LS cocktail, Groningen, Netherlands). All other chemicals of 
analytical grade were purchased from Sigma (St. Louis, MO). 
 
Poly((polyvinyl alcohol)-g-(D,L-lactide-co-glycolide)) 
Synthesis and characterisation were carried out as described earlier 
[16,19]. Briefly, comb polyesters were synthesised by a stannous octoate 
catalysed ring-opening polymerisation of lactide and glycolide (1:1) in the 
presence of the backbone poly(vinyl alcohol) (PVA; MW 15 kg/mol, degree of 
polymerisation 300, degree of hydrolysis 88%) under anhydrous conditions. The 
polymers used for film preparation are described in Tab. 1. The following 
nomenclature will be used to specify the polymers: PVA300-g-PLGA(XX). The 
number in parenthesis refers to the mass ratio of branched PLGA, which is 
grafted (g) onto the hydrophilic backbone, compared to the PVA. 
 
Preparation of polymer films 
Films were cast from an acetone solution of the polymers (5% w/v) on 
teflon plates containing paclitaxel in specified concentrations. After 72 h of 
solvent evaporation films were cut into discs using a punch cutter. The films 
were dried for three days in a drying chamber under reduced pressure at room 
temperature until constant weight was obtained. 
 
Differential scanning calorimetry (DSC) 
Glass transition temperatures (Tg) were measured using a differential 
scanning calorimeter (DSC7, Perkin Elmer, Germany). Film samples (5 mg) 
were sealed in aluminium pans and heated twice in a nitrogen atmosphere. 
Thermograms covering a range of (-)10°C to 220°C were recorded at a heating 
and a cooling rate of 10 °C per minute. The second run was used for Tg 
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calculation (Pyris Software, Perkin Elmer, Germany). Calibration of the system 
was performed using gallium and indium standards. 
 
Wide angle X-ray diffraction (WAXD) 
X-ray diffraction pattern of paclitaxel powder and paclitaxel-loaded films 
were recorded on a D-5000 diffractometer (Siemens, Germany) equipped with 
DiffracPlus 3.0 software (Bruker Rheinstetten) at room temperature. The scan 
range of 2θ was 2 to 30° at a rate of 1°2θ / min. The X-ray source was nickel 
filtered CuKα radiation (λ= 1.54 A). 
 
Size exclusion chromatography (SEC) 
Polymer solutions were injected into a thermostatted (60°C) Merck-
Hitachi system (column: SDV linear M 8×300 mm with a pre-column 8×50, 5 
µm, Polymer Standard Service, Germany) equipped with a differential 
refractometer (RI 71) and a light scattering detector (MiniDawn, 100 µl K5 cell, 
GaAs laser 690 nm, laser power 30 mV). Chromatograms were obtained with 
N,N-dimethylacetamide containing lithium bromide (2.5 g/l) at a flow rate of 0.5 
ml/min. Molecular weights were calculated using ASTRA V4.73 software 
(Wyatt, Technology Corp., CA). 
 
Scanning electron microscopy (SEM) 
The morphology of prepared films and coated stents was characterised by 
SEM using a Hitachi S-4100 microscope (Hitachi, Germany). Dried specimens 
were mounted on aluminium pins using double-sided adhesive tape. Prior to 
microscopic examination samples were sputter coated with a gold layer under 
vacuum for 30 seconds (Edwards Auto 306, Edwards, Germany). 
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No. Polymer Polymer properties 
  Mw PVA 
(kg/mol) 
Mw a 
(kg/mol) 
Mn a 
(kg/mol) 
side chain 
lengthb 
ratio 
lactide:glycolide 
Tgc 
(°C) 
1 PVA300-g-PLGA (15) 15 249.9 178.7 17.8 1:1 27.0 
2 PVA300-g-PLGA (30) 15 438.1 319.1 31.7 1:1 28.8 
3 Linear PLGAd - 28.4 - - - 37.96 
 
a determined by SEC (size exclusion chromatography) combined with MALLS (multi angle laser light scattering) 
   using N,N dimethylacetamide containing 2.5 g/l LiBr as eluent. 
b PLGA side chain length determined from 1H-NMR. 
c Tg (glass transition temperature) determined using differential scanning calorimetry 
   (temperature range (-)10 – 220 °C; heating/cooling rate 10 °C/min) 
d RG503H, supplied by Boehringer Ingelheim, Germany 
 
Tab. 1:  Characteristics of biodegradable polymers based on PVA 300-g-PLGA comb polyesters and PLGA. 
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Fig. 1: Schematic illustration of functional and morphological changes of the 
double coated stent surface after stent implantation (A). Primary coating of PPX 
(Parylene N), covering the total stent surface, is generated using chemical 
vapour deposition (CVD). The outer, lesion site directed stent surface is coated 
with a paclitaxel (Ptx) containing and biodegradable layer based on PVA-g-
PLGA using air brush method. PVA-g-PLGA coating degrades, the Ptx is 
released towards the vessel wall, and prevents excessive proliferation of smooth 
muscle cells, while the vascular lesion is able to heal (B). After degradation of 
the drug eluting layer, the PPX coating remains on the stent surface and ensures 
stent endothelization and long lasting stent compatibility to the surrounding 
vascular tissue. 
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In vitro degradation of polymer films 
Polymer films from PVA300-g-PLGA(30) (18.00 ± 1.65 µm thickness) 
with paclitaxel loadings of 5 and 15 % were prepared as described above. 
Samples of known weight (39.66 ± 2.41 mg) were immersed in 5 ml phosphate 
buffered saline solution (PBS, 0.05M, pH 7.4) in glass vials and stored at 37°C. 
The buffer medium was periodically replaced during incubation experiments. At 
defined time intervals samples were recovered, washed with demineralised 
water, and subsequently lyophilised for 48 h followed by secondary drying at 
room temperature in vacuum for 7 days. To characterise the degree of 
degradation molecular weights (SEC), mass loss (gravimetrically) and film 
morphology (SEM) were investigated. Water uptake was determined 
gravimetrically after the water on the surface was removed by blotting. It was 
calculated as follows: Water uptake (%) = 100 – (Mass(t)wet/Mass(t)dry × 100). 
Each sample was determined in triplicate. 
 
In vitro paclitaxel release 
For in vitro release of drug loaded films 14C-labelled and non-labelled 
paclitaxel were mixed in a mass ratio of 1 to 250 to a final theoretical loading of 
5%. Films from PVA300-g-PLGA(15), PVA300-g-PLGA(30), and PLGA were cut 
into discs of 6 mm in diameter, which were incubated in 2 ml of different buffer 
solutions in glass vials at 37°C. At defined time intervals the buffer was 
withdrawn and 2 ml of fresh medium was added to the films. One milliliter of 
the supernatant was mixed with 5 ml of scintillation cocktail (Ultima Gold). 
The activity of radio labelled paclitaxel for calculation of total drug release was 
quantified by liquid scintillation counting (LSC) (Tri-Carb 2900TR, Packard 
BioScience, Germany) at a counting time of 5 minutes for each sample. All 
measurements were performed in triplicate. 
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Stent coating 
Stents consisting of stainless steel (length 48 mm, diameter of 3.12 mm) 
(JOSTENT peripheral, JOMED Implantate GmbH, Germany) were coated 
with poly (para-xylylene) (PPX) by using chemical vapor deposition (CVD) 
method [18]. In a next step the PPX layer was swollen in chloroform and 
covered by a second polymer layer consisting of PVA300-g-PLGA(15) or 
PVA300-g-PLGA(30) by using the spray coating method. For this purpose a 
polymer solution of 1 % (w/w) in chloroform was sprayed onto the stent surface 
at a distance of 5 cm using an air brush (Model Aero-pro Classic 10, Hansa, 
Germany) and dried under vacuum for 2 days at room temperature prepared for 
scanning electron microscopy analysis as described above. Stents were 
examined in the non-expanded state and after dilatation of tempered devices 
(37°C) from 3.12 to 5 mm by crimping on a thorn of stainless steel. 
 
RESULTS AND DISCUSSION 
The aim of this study was the evaluation of PVA-g-PLGA comb 
polyesters for the preparation of paclitaxel eluting stent coatings. The insertion 
of a hydrophilic backbone PVA into hydrophobic PLGA chains led to a more 
continuous drug release profiles [16]. The modification of PLGA chain length 
allowed the adjustment of the drug release from coated stents to the clinical 
requirements of drug delivery. Factors contributing to paclitaxel release from 
polymer films are most notably balance of hydrophobic and hydrophilic 
components, glass transition temperature (Tg), as well as degradation (loss of 
molecular weight) and erosion (mass loss) kinetics. 
The glass transition temperature (Tg) of polymers has an important effect 
on the drug release [20], and above all, on the flexibility of the stent coating, 
which is important for the film integrity during stent crimping and implantation 
using balloon catheters. Tab. 2 displays the Tg of two different PVA-g-PLGAs 
and linear PLGA. The Tg of pure linear PLGA is 9 °C higher compared to Tg of 
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PVA-g-PLGA(30) (28.8 °C). By decreasing the PLGA chain length the Tg 
decreases, as seen for PVA-g-PLGA(15) (27.0 °C). Thus, flexibility of polymer 
film increases, which is important for the matrix integrity after stent expansion 
inside the treated vessel segment. The incorporation of paclitaxel reinforces the 
decrease of glass transition temperature by increasing the drug loading. The shift 
of the Tg of polymers to lower temperatures is due to the drug, which is at least 
partly molecularly dispersed in the polymer matrix. The drug acts as a plastiziser 
that influences flexibility of films at body temperature. 
 
Glass transition temperature 
[°C] Polymer 
Loading [%] 0 5 10 15 
PVA300-g-PLGA(15) 27.0 25.4 21.9 21.3 
PVA300-g-PLGA(30) 28.8 26.8 22.7 21.6 
Linear PLGA 37.96 27.3 25.6 24.5 
Tab. 2: Glass transition temperature of paclitaxel loaded films determined using 
differential scanning calorimetry (scanning range – 10 to 220 °C, 
heating/cooling rate 10 °C/min). 
 
Moreover, by using SEM morphological changes of films were observed 
by increasing the drug loading (Fig. 2). Paclitaxel-free films exhibited a smooth 
surface without pores and corrugations. Although thermograms obtained using 
DSC did not show any melting point for paclitaxel, films became partly rough 
and round, and furthermore, rosette-like structures were observable on the 
surface by increasing the paclitaxel content up to 15%. This phenomenon could 
be explained by the slight paclitaxel mass in the samples which was possibly 
under the detection limit of DSC. For this reason we used WAXD to 
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characterise the dispersion state of paclitaxel at different loadings more detailed 
(Fig. 3). 
 
Fig. 2: Scanning electron microscopy (SEM) images of paclitaxel (Ptx)-loaded 
films prepared from (a - c) PLGA, (d - f) PVA300-g-PLGA(30), and (g - i) 
PVA300-g-PLGA(15) with drug loadings of 5 % (a, d, g), 10 % (b, e, h) and 15 % 
(c, f, i). 
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At drug loadings of less than 10 % WAXD profiles did not show any 
peaks of crystallised drug similar to those of unloaded polymer films (not 
shown) suggesting that the paclitaxel is soluble in the polymer matrix. 
Contrastingly, at a drug content of ≥ 10% WAXD patterns of films became more 
irregular, and crystallisation peaks were slightly increased. Similar results were 
reported by Jeon et al. (2000) who observed a concentration dependent 
norfloxacin crystallisation in PLGA nanoparticles using WAXD [21]. Several 
diffraction maxima are present at the same 2Θ as observed in the diffractogram 
of paclitaxel. There is evidence that drug and polymer formed a solid dispersion. 
Due to the high drug levels lipophilicity of polymer matrix increases and may 
decelerate polymer degradation. 
(a) (b) (c) 
Fig. 3: Wide angle X-ray diffraction pattern of paclitaxel and paclitaxel (Ptx)-
loaded films prepared from (a) PLGA, (b) PVA300-g-PLGA(30), and (c) PVA300-
g-PLGA(15) with drug loadings of 5, 10, and 15%. 
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The polymer composition dependent paclitaxel release is described in Fig. 
4. Drug liberation was performed in normal phosphate buffered saline (PBS) 
(Fig. 4a), and in PBS containing human serum albumin (HSA, 1%) (Fig. 4b). 
Protein carriers, e.g. serum albumin (SA) or α1-acid glycoprotein (αGP) tend to 
bind to polymer surfaces and other hydrophobic compounds. Association of 
drugs with tissue fixed proteins have a retaining effect within the treated vessel 
segment, limiting their distribution from the target tissue [22-24]. For this reason 
we also examined the influence of HSA on the paclitaxel release behavior. In 
case of PLGA, an initial lag phase is followed by a more rapid release as a 
consequence of polymer erosion leading to a sigmoidal liberation profile of 
paclitaxel in both, HSA containing and HSA free medium. Similar release 
kinetics were reported for a paclitaxel-eluting stent system (Conor Medstent, 
MedSystems) which contains strut elements with stacked layers of drug and 
PLGA. Initial and late release rates were controlled by adding top and bottom 
polymer layers [25]. Biphasic release profiles were described for the TAXUS 
NIRx paclitaxel-eluting stent with an initial burst within the first 24 h followed 
by a slow release over a 10 days period. The drug was incorporated in a 
copolymer system. Release rates were altered via the drug/polymer ratio and 
coating thickness [26]. The stent used in the RAVEL study is coated with a 
nonerodable mixture of poly(ethyl methacrylate) and n-butylmethacrylate 
blended with sirolimus, a immunosuppressive agent with anti-proliferative 
properties [27,28]. To regulate drug release an inert coating is applied as 
diffusion barrier that provides a controlled release rate of 80 % within a time 
period of 30 days. In contrast to PLGA coatings, PVA-g-PLGA films did not 
reveal any burst release. Furthermore, release rates from PVA-g-PLGA devices 
were clearly improved resulting in more continuous and linear release profiles, 
particularly in the albumin containing phosphate buffer system (Fig. 4b). 
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Fig. 4: In vitro release of paclitaxel from polymer films of PVA300-g-PLGA and 
linear PLGA in (a) PBS (0.05M, pH 7.4), and (b) in PBS containing 1% human 
serum albumin (HSA). 
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Fig. 5: (a) Water uptake, (b) mass loss (Mw) and (c) molecular weight of 
PVA300-g-PLGA(30) loaded with 5 (full circles) and 15% (open circles) 
paclitaxel in 0.05M PBS, pH 7.4, 37°C. 
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After 48 days 83 % of the incorporated paclitaxel was released from the PLGA 
matrices, whereas 56 to 64 % of the drug was liberated from the PVA-g-PLGA 
films at the same time. Only small differences in release rates of branched 
polyesters could be observed. Nevertheless, the paclitaxel release tends towards 
a slightly faster paclitaxel release from PVA-g-PLGA(15) films in contrast to 
those of PVA-g-PLGA(30). To achieve faster release rates, it would be useful to 
study PVA-g-PLGA films with a lower PLGA substitution. 
Breitenbach et al. (2000) previously proposed a bulk erosion mechanism 
for PVA-g-PLGA with a high PLGA content, whereas polymers with a lower 
PLGA rate erodes in a more surface front-like manner [16]. But the question is 
in which way paclitaxel was released, and how the drug-loading influences the 
degradation and erosion properties of PVA-g-PLGA? For this reason we 
investigated mass and molecular weight loss as well as water uptake of PVA-g-
PLGA(30) films with paclitaxel loadings of 5 and 15%, exemplarily. As 
depicted in Fig. 5a the amount of incorporated lipophilic drug influenced the 
water uptake within the first 12 days of incubation with PBS, which is increased 
for the films with 5% paclitaxel. Due to the mass and molecular weight loss rate 
of films with 5% and 15% paclitaxel were found to be constant and almost 
equal. Without an initial lag phase the film mass decreased at a constant rate 
during 42 days of incubation (Fig. 5a), which is in agreement with the surface 
erosion mechanism for low molecular weight PVA-g-PLGA. The profile for 
molecular weight loss (Fig. 5b) is comparable to those, observed for bulk 
erosion of linear PLGA [16]. In addition, the examination of morphological 
changes of incubated films by scanning electron microscopy could not clarify 
the degradation mechanism considerably and revealed indications for both 
surface front-like and bulk erosion mechanism. Fig. 6 shows a time-series of 
SEM images after incubation with PBS. The initially smooth surface was found 
to be porous after 7 days. Further on, pore development in the inner phase was 
observed. The pore density and size increased with time up to 35 days of 
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incubation. Film surface became irregular, rough and porous progressively. 
Nevertheless, the release behaviour of lipophilic paclitaxel from PVA-g-PLGA 
films is well controllable by using PVA-g-PLGA polyesters, exhibiting 
sustained, and clearly improved release profiles in contrast to PLGA. 
 
Fig. 6: Typical scanning electron micrographs of eroding PVA300-g-PLGA(30) 
films after 7 and 35 days of incubation: (A) and (B) 5%  paclitaxel, (C) and (D) 
15% paclitaxel. 
 
Besides pharmacokinetic requirements of drug delivery vehicles, 
polymeric coatings have to be resistant during stent implantation and expansion. 
Therefore, we investigated the morphology of PVA-g-PLGA coated stents 
before and after stent expansion from 3.12 mm to 5 mm by scanning electron 
microscopy (Fig. 7). It turned out that a brand new stent showed deposition of 
impurities on the metal surface, which may deposited during manufacturing 
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process (Fig. 7a and 7b). The polymeric layers were able to mask these 
impurities and to smooth the surface. Partly, the coated stent showed small pits 
indicating that the PVA-g-PLGA layer is very thin or incomplete at these sites. 
Nevertheless, after stent dilatation the polymer films exhibited adherence to the 
greatest possible extent (Fig. 7c and 7e). Except for some cracks at the 
mechanical stressed sites of the stent struts, the integrity of the coating was not 
affected, as displayed in Figure 7d and 7f. 
 
Fig. 7: Scanning electron microscopy images of Jostent peripheral stent 
implants: bare metal stent (a), (b). Stent coated with Parylene N and PVA300-g-
PLGA(30) (c), (d), and with Parylene N and PVA300-g-PLGA(15) (e), (f) in 
different magnifications. 
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CONCLUSIONS 
Drug eluting stents represent an interesting field in interventional vascular 
surgery. Several drug delivery devices have shown tremendous promise in the 
long –term prevention of restenosis. We were able to synthesize biocompatible 
and biodegradable polyesters by grafting PLGA chains onto a PVA backbone, 
which showed good mechanical stability and adherence on Parylene N coated 
stent surfaces after stent expansion. Physico-chemical properties of paclitaxel-
loaded films were studied using differential scanning calorimetry (DSC) and 
wide angle X-ray diffraction (WAXD). By increasing drug loading the film 
matrices turned from a solid solution into a solid dispersion at higher paclitaxel 
amounts. Furthermore, PVA-g-PLGA polymers provide a controlled and 
continuous paclitaxel release. With respect on the variability and proved 
biocompatibility, PVA-g-PLGA comb polyesters seem to be promising 
candidates for sustained release of lipophilic drugs like paclitaxel, and, based on 
recently published data [17], additionally for the release of hydrophilic, 
macromolecular drugs, such as peptides, proteins, or DNA, which are of note in 
the treatment of restenosis as well. However, further studies are necessary to 
optimize the coating method, and prove possible deleterious effects on the 
coating integrity during incubation with buffer solution in-vitro, and after 
sterilisation. 
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SUMMARY 
Despite improved technologies restenosis remains the main problem of 
catheter-based interventions after a percutaneous transluminal angioplasty in 
artery disease. Local and sustained application of antiproliferative agents is a 
promising approach to solve the problem of intimal hyperplasia. In recent years, 
two different concepts for local drug delivery have attained increased 
importance: On the one hand, colloidal drug carriers, which can be infused 
directly into the vessel wall during the angioplasty procedure using special 
delivery catheters and on the other hand, the development of drug eluting stents. 
Biocompatible, biodegradable polymers are one of the most important 
instruments used to control the release of pharmacological active substances. A 
new type of branched, biodegradable polyesters, poly(vinyl alcohol)-graft-
poly(lactide-co-glycolide) (PVA-g-PLGA), possesses very interesting features 
for the local and sustained release of paclitaxel. Therefore, the objective of this 
work was to investigate these polymers with regard to the preparation of 
paclitaxel loaded nanoparticles and stent coatings, and to evaluate their 
applicability as drug carriers to prevent intimal hyperplasia. 
As a result of a poor delivery efficiency and intramural retention of 
infused agents, researchers have developed colloidal drug carrier systems from 
biodegradable polymers, which can be administered to the arterial vessel wall 
using porous balloon catheters. Several studies have demonstrated that particle 
size plays an important role in the penetration and cellular uptake, as described 
in Chapter 2. In this study the size dependent penetration and distribution of 
fluorescently labelled polystyrene nanoparticles (110, 217, and 514 nm in 
diameter) was investigated after local delivery into the vessel wall of the aorta 
abdominalis of New Zealand white rabbits using confocal laser scanning 
microscopy (CLSM). In contrast to recently reported observations, the examined 
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cross-sections did not show severe disruptions of the vessel wall. While 
nanoparticles of ≤ 217 nm deposited predominantly in the medial layer, 514 nm 
nanoparticles accumulated at the luminal surface. Furthermore, formation of 
pressure induced infusion channels was observed. When using transmission 
electron microscopy (TEM) to evaluate deposition, nanoparticles of 110 and 217 
nm in size were found within the media and along the elastica lamina externa. 
Atherosclerotic plaques and elastic connective tissue were shown to act as 
strong anatomical barriers influencing penetration and permeation behavior of 
nanoparticles. 
In addition to particle size other parameters, such as infusion pressure, 
particle suspension volume, as well as particle concentration, play an important 
role in catheter-based delivery. The effects of these factors on intraluminal 
particle distribution were investigated by CLSM, SEM, and TEM after infusion 
of fluorescently labelled polystyrene nanoparticles of 217 nm, as described in 
Chapter 3. Our results demonstrated pressure dependent particle migration 
through the vessel wall tissue, as characterized by channel-like deposition 
patterns corresponding to the porous balloon catheter design. Nanoparticles were 
localized in the intima, media, and adventitia. The infusion of 2 ml of a particle 
suspension (1 mg/ml) at an infusion pressure of 4 bar promoted delivery 
efficiency without causing severe vessel wall ruptures. In contrast, an increase in 
the suspension volume to 5 ml could not improve the delivery efficiency. The 
capacity of the vascular tissue at the delivery site appears to be small resulting in 
an escape of the solution or suspension into the blood stream. Possibly, large 
volumes may cause additional vessel ruptures. As a result of the interventional 
procedure the treated vessel segments showed partial damage and denudation of 
the endothelial layer. In spite of improved techniques, these injuries were 
difficult to avoid. Apart from the penetration characteristics observed, TEM 
images from cross and longitudinal sections of the vessel displayed vasa vasora 
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with nanoparticle incorporations, thus confirming results in recent studies, 
which described the transport properties of these small vessels. The vasa vasora 
is a network of small vessels spread throughout the adventitia and in the larger 
vessels can penetrate the media to supply the vessel wall. 
The next step of this work included the preparation of paclitaxel loaded 
nanoparticles using the solvent evaporation technique and subsequent 
characterization of nanopartilce size, shape, yield, and encapsulation efficiency. 
Further experiments, detailed in Chapter 4, provided information about the drug 
release, the cytotoxicity of loaded and non-loaded nanoparticles, as well as their 
uptake into rabbit vascular smooth muscle cells (RbVSMC) in-vitro. PVA-g-
PLGA nanoparticles were characterized by photon correlation spectroscopy 
(PCS), scanning electron microscopy (SEM), and atomic force microscopy 
(AFM). It was shown that NP formulations consist of round spheres with 
smooth surfaces and had a mean particle diameter of 140 to 180 nm in size. 
Particle yields typically ranged from 80 to 95 % with encapsulation efficiencies 
between 77 and 87 %. A decrease in the PLGA fraction of the polymer resulted 
in an increase in drug release rates. After an initial burst release, a slow, but 
continuous release for about 22 days was observed. The burst effect could be 
desirable to achieve high initial drug concentrations in the target tissue. After 
release of the loading dose, the subsequent sustained drug release rate should be 
substantial enough to obtain a constant drug level in the tissue and prevent 
excessive VSMC proliferation. Blank nanoparticles from PVA300-g-PLGA(30) 
and PVA300-g-PLGA(15) showed a high biocompatibility to RbVSMC at 
particle concentrations of 370 µg per ml. Paclitaxel-loaded NP possess an 
increased anti proliferative effect in comparison to the free drug. This indicated 
an improved cellular uptake of nanoparticles. CLSM of RbVSMC confirmed 
uptake of nanoparticles composed of 7-methoxycoumarine labelled PVA300-g-
PLGA(15) (blue fluorescence) loaded with Oregon Green labelled paclitaxel 
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(green fluorescence) after a 6 hour incubation period. Based on previous 
observations, the mechanism for NP uptake and intracellular distribution could 
be characterized as pinocytosis or/and endocytosis, followed by transportation to 
endosomes. 
In Chapter 5 the focus was shifted from NP to polymeric stent coatings 
consisting of PVA-g-PLGA, which were designed to provide a controlled and 
sustained release of paclitaxel. Drug release rate were influenced by the polymer 
structure. In contrast to release from NP, film matrices prepared from PVA-g-
PLGA(30) and PVA-g-PLGA(15) showed a more continuous release. In 
contrast, linear PLGA exhibited a sigmoid, non linear paclitaxel release. A 
decrease of PLGA side chain length, as well as an increase of drug loading leads 
to lower glass transition temperatures (Tg) influencing the flexibility of the films 
which is an important aspect due to the coating integrity during stent crimping 
and implantation. At drug loadings of more than 10 %, wide angle X-ray 
diffraction (WAXD) patterns of films confirmed paclitaxel crystallization within 
the films, which influenced water uptake obviously due to the lipophilicity of 
the substance. As a result, the influence of drug loading on the mass loss and 
molecular weight (Mw) loss was investigated by incubation of film devices 
made from PVA-g-PLGA(30) with 5 and 15% paclitaxel. Matrices with 5% 
paclitaxel exhibited increased water uptake within 12 days. Film mass and Mw 
of the polymer decreased in a linear manner within 42 days independent of the 
degree of loading. The results suggest a more heterogonous mechanism of 
degradation including surface and bulk erosion. Scanning electron micrographs 
gave the impression of time-dependent changes in device morphology during the 
incubation period. Metallic stent implants were coated with PVA-g-PLGA(30) 
and PVA-g-PLGA(15) using an air brush technique, to examine film integrity 
after stent expansion from 3.12 to 5 mm. With except of minor crack formation 
at the mechanically stressed sites of the stent SEM analyses demonstrated total 
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film adhesion. Furthermore, impurities on the surface and a partly non-uniform 
thickness of the coating was observed. To conclude, comb polyesters are 
potential candidates for controlled release matrices coated on stent implants, 
although findings reinforce the fact that further work is necessary to optimize 
the coating procedure. 
 
OUTLOOK FOR FURTHER STUDIES 
Based on the results from in-vitro characterization of paclitaxel-loaded 
nanoparticles, animal studies may be useful to elucidate the efficiency of 
colloidal drug carriers in vivo [1]. The infusion of fluorescently- or radio-
labelled substances encapsulated into nanoparticles could help to further 
characterize the diffusion pathways and deposition patterns within the arterial 
vessel wall using CLSM or autoradiography. 
As already mentioned, the air brush technique for stent coating needs 
further optimization. Direct modification of parameters, such as spraying 
distance, duration, polymer concentration, or viscosity of the polymer solutions, 
may be useful to control film thickness according to the desired clinical 
requirements. Another important aspect of stent-based drug delivery technology 
is the investigation of mechanical properties of the polymers. The polymer 
coating must be durable enough to withstand handling during crimping onto the 
balloon catheter yet elastic enough to endure the expansion of the stent. The 
coating must also adhere to the surface under in vitro and in vivo conditions and 
remain stable during the sterilization process, which includes alterations in 
molecular weight, polydispersity, and release behavior [12]. 
The potential of comb polyesters (PVA-g-PLGA) has already been 
demonstrated in recent studies [13,14]. The variability of the polymer 
composition and the possibility of grafting positively [15] or negatively charged 
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structures [16,17] to the polymer backbone offers great flexibility for the 
incorporation of both hydrophilic and hydrophobic substances, i.e. polymer 
properties can be adjusted to suit those of the drug molecules. Therefore, another 
impulse for further investigations may be the use of other, potentially 
antirestenotic drugs. Some promising candidates are summarized in Tab. 1. 
 
Substance Mechanism of action Lit. 
Antiproliferative agents    
Sirolimus inhibits production of proteins essential for cell division, 
immunsuppressive and antiproliferative properties 
[2] 
Tacrolimus see Sirolimus [3] 
Angiopeptin Somatostasin analogue; inhibits many cytokines and growth factors; 
potentially antiproliferative effects 
[4] 
Tyrosin kinase 
inhibitor 
interfere with intracellular cell signalling that regulate cell 
proliferation and differentiation [5] 
Antisense oligonucleotides against   
NFκB inhibition of activation of many cytokines, growth factors; anti-inflammatory, antiprolifarative effect [6] 
E2F decoy  transcription factor; blocking the activation of genes mediating the cell cycle; antiprolifarative effect [7] 
c-myc inhibition of the cell cycle; antiprolifarative effect [8] 
Others   
VEGF stimulate endothelial proliferation; avoiding intimal hyperplasia [9] 
Saratin inhibit von Willebraband factor-depending platelet adhesion; decrease platelet aggregation; potentially avoiding intimal hyperplasia [10] 
Iloprost prostacyclin analogue; antithrombotic potentially antiproliferative [11] 
Tab. 1: Potential candidates for incorporation into colloidal or film matrices 
composed of PVA-g-PLGA comb polyesters. 
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ZUSAMMENFASSUNG 
Trotz verbesserter Techniken ist die Entwicklung einer Restenose nach 
einer perkutanen transluminalen Angioplastie (PTA) atherosklerotischer Gefäße 
weiterhin eines der zentralen Probleme katheterinterventioneller Therapien. 
Daher könnte die lokale und anhaltende Applikation antiproliferativ wirkender 
Substanzen einen wesentlichen Beitrag zur Vermeidung einer Restenose leisten. 
In den letzten Jahren kristallisierten sich zwei verschiedene Applikationssyteme 
heraus. Zum einen Wirkstoff-beladene Nanopartikel, die während der 
Gefäßdilatation durch spezielle Ballonkatheter direkt in die Gefäßwand injiziert 
werden. Zum anderen erfahren Wirkstoff-beschichtete Stents eine immer größer 
werdende Aufmerksamkeit in Forschung und Klinik. Biokompatible und 
bioabbaubare Polymere werden hierbei zu einem wichtigen Instrument. Sie 
sollen ein kontrolliertes Freisetzen definierter Mengen eines Wirkstoffes 
gewährleisten. Eine neue Klasse bioabbaubarer Polymere, die sogenannten 
Kammpolymere (PVA-g-PLGA), scheinen für die lokale und anhaltende 
Applikation von Paclitaxel sehr geeignet zu sein. Aus diesem Grund war es Ziel 
der vorliegenden Arbeit, diese Polymere zur Herstellung von Paclitaxel-
beladenen Nanopartikeln sowie Stentbeschichtungen zu verwenden, und deren 
Eignung als Trägersyteme zur Therapie einer Restenose zu überprüfen. 
Aufgrund einer zu geringen Verweildauer und damit auch geringen 
Wirksamkeit lokal applizierter Wirkstofflösungen, wurden kolloidale, 
bioabbaubare Trägersysteme entwickelt, die mit Hilfe von perforierten 
Ballonkathetern während einer PTA in die Gefäßwand eingebracht werden. 
Dabei spielt die Partikelgröße eine wichtige Rolle für die Applikationseffizienz, 
die in Kapitel 2 genauer untersucht wurde. Hierfür wurden Fluoreszenz-
markierte Polystyrolnanopartikel mit einem Durchmesser von 110, 217 und 514 
nm in die Gefäßwand der Aorta abdominalis von weißen Neuseeland Kaninchen 
appliziert, und die Partikelverteilung mit Hilfe der konfokalen Laser Scanning 
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Mikroskopie (CLSM) untersucht. Während der Applikation in unserem Modell 
entstanden im Gegensatz zu einigen früheren Studien keine Gefäßrupturen. 
Während Nanopartikel ≤ 217 nm vor allem im Zielgewebe, der Media, detektiert 
wurden, zeigte sich, dass sich die 514 nm Nanopartikel vor allem auf der 
luminalen Oberfläche abschieden. Im weiteren konnten kleinere, 
druckinduzierte Infusionkanäle beobachtet werden. Zur präziseren Lokalisierung 
der Nanopartikel in den einzelnen Geweben diente die 
Transmissionselektonenmikroskopie (TEM). So wurden Partikel von 110 und 
217 nm zwischen den glatten Muskelzellen der Media und perlenkettenartig 
entlang der Elastica lamina externa gefunden, während sich 514 nm große 
Partikel vor allem in der Endothelschicht befanden. Anatomische Barrieren, wie 
das dichte Bindegewebe der Elastica lamina interna und externa, können hierbei 
eine Verteilung der Partikel im Gewebe beeinflussen. 
Neben der Partikelgröße spielen auch andere Applikationsparameter eine 
wichtige Rolle. So wurden in Kapitel 3 Infusionsdruck, Volumen und 
Konzentration der Partikelsuspension untersucht. Lokalisierung und 
Penetrationscharakteristika Fluoreszenz-markierter Polystyrolnanopartikel 
(217 nm) in der Arterienwand wurden mit Hilfe von CLSM, TEM und 
Rasterelektronenmikroskopie (REM) analysiert. Dabei bildeten sich an einigen 
Stellen in der Gefäßwand Infusionskanäle aus, deren Durchmesser an der 
lumenseitigen Infusionstelle dem der Katheterporen entsprach. Die Partikel 
waren in Intima, Media und Adventitia zu finden. Die Verwendung von großen 
Partikelkonzentrationen (1 mg/ml), einem Suspensionsvolumen von 2 ml und 
Infusionsdrücken von 4 bar war hierbei am effektivsten bei gleichzeitiger 
Vermeidung zusätzlicher Gefäßtraumata. Das arterielle Gewebe scheint nicht in 
der Lage zu sein, sehr große Suspensionsvolumina aufzunehmen. Zum einen 
würde ein Großteil durch das Lumen und den Blutkreislauf abfließen. Zum 
anderen könnten wiederum Gefäßrupturen entstehen. Die Katheterintervention 
 Chapter 6 118 
  
hatte sichtbaren Einfluss auf die Integrität der Endothelschicht, wie 
elektromenmikroskopische Aufnahmen verdeutlichten. Das Endothel wurde 
partiell durch den Katheter verletzt und sogar abgetragen. Diese Verletzungen 
sind trotz verbesserter Techniken bis jetzt kaum zu vermeiden. Im Weiteren 
bestätigten transmissionselektronenmikroskopische Untersuchungen der 
infundierten Arterienabschnitte, dass auch die Vasa vasora für einen 
Nanopartikeltransport innerhalb der Arterienwand verantwortlich sind. 
Die wichtigen Erkenntnisse zur Charakteristik der Partikelpenetration 
durch Variation verschiedener Parameter, ließ nun eine gezielte Herstellung 
Paclitaxel-beladener Nanopartikel entsprechender Größe zu, um diese dann 
später auch in einen in-vivo Tiermodell testen zu können. Doch zunächst 
mussten PVA-g-PLGA Nanopartikel, hergestellt mittels „Solvent –
Displacement“- Technik, bezüglich Größe, Aussehen und Beladungsgrad 
genauer charakterisiert werden. Desweiteren sollten Versuche zur 
Paclitaxelfreisetzung, sowie Zytotoxizität und Partikelaufnahme an glatten 
Muskelzellen der Aorta abdominalis aus weißen Neuseeland Kaninchen, die 
Eignung der Partikel in vitro unter Beweis stellen, wie in Kapitel 4 beschrieben 
wurde. Die zwischen 140 und 180 nm großen, monodispers verteilten NP hatten 
eine kugelige Form und eine glatte Oberfläche, wie Untersuchungen mit 
Rasterelektronen- und Rasterkraftmikroskopie zeigen konnten. Die 
Partikelausbeute lag zwischen 85 und 90%, während Verkapselungsausbeuten 
von 77 - 87% erzielt wurden. Mit zunehmendem PLGA-Anteil im Polymer, 
konnte auch die Freisetzungsgeschwindigkeit erhöht werden. Nach einem 
großen Wirkstoffburst während der ersten 24 Stunden der in vitro Freisetzung, 
flachten die Freisetzungsprofile der untersuchten Partikelchargen stark ab, und 
das Paclitaxel wurde langsam aber kontinuierlich über einen Zeitraum von 22 
Tagen freigesetzt. Ein initialer Burst muss aber zwangsläufig keinen Nachteil 
darstellen. So kann dadurch zu Beginn eine hohe Wirkstoffkonzentration 
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(Initaldosis) im Zielgewebe erreicht werden, um diese im Weiteren mit einer 
langsamen, aber konstanten Freisetzung zu stabilisieren (Erhaltungsdosis). 
Während nicht beladene NP aus PVA300-g-PLGA(30) und PVA300-g-PLGA(15) 
in Konzentrationen bis etwa 370 µg/ml im Wesentlichen untoxisch waren, 
zeigten beladene PVA-g-PLGA NP gegenüber unverkapseltem Wirkstoff eine 
gesteigerte Hemmung der metabolischen Aktivität des glatten Muskelzellen. 
Dies könnte auf eine verbesserte Aufnahme der NP in die glatten Muskelzellen 
zurückzuführen sein, wie mit Hilfe der CLSM beobachtet werden konnte. 
Hierzu wurde 7-Methoxycoumarin markiertes PVA-g-PLGA(15) (blaue 
Fluoreszenz) zur Verkapselung von Oregon Green markiertem Paclitaxel (grüne 
Fluoreszenz) verwendet. Sowohl die Polymerpartikel als auch das verkapselte 
Paclitaxel waren nach einer Inkubationszeit von 6 h deutlich in der Zelle zu 
sehen. Mögliche Aufnahmemechanismen wurden bereits vielfach in der 
Literatur diskutiert. Demnach wäre eine Aufnahme der Nanopartikel durch Pino- 
und/oder Endocytose mit anschließendem Transport zu Endosomen. 
Abschließend wurden, wie in Kapitel 5 beschrieben, die Eigenschaften 
von Polymerfilmen aus PVA-g-PLGA untersucht. Aufgetragen auf eine 
metallische Gefäßprothese (Stent) sollen sie eine kontrollierte und anhaltende 
Paclitaxelfreisetzung gewährleisten. Wie schon bei den Nanopartikeln 
beobachtet, so war auch bei den Filmen die Freisetzungsgeschwindigkeit von 
der Polymerzusammensetzung abhängig. Allerdings zeigten die Filme ein fast 
lineares Freisetzungsprofil. Die Erniedrigung der PLGA-Kettenlänge, wie auch 
die Erhöhung der Wirkstoffbeladung führen zu einer Erniedrigung der 
Glasübergangstemperatur (Tg) der Polymere. Die Polymerfilme werden dadurch 
weicher und flexibler, was wiederum ein wichtiger Aspekt bezüglich der 
Filmintegrität während der Fixierung auf dem Ballonkatheter und nach der 
Implantation in das Gefäß ist. Bei Beladungen der Filmmatrix mit mehr als 10% 
Wirkstoff konnte mittels Weitwinkelröntgendiffraktometrie (WWRD) 
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festegestellt werden, dass sich zunehmend Kristallnester des Wirkstoffs bildeten. 
Die Veränderungen der Matrix konnten auch durch 
rasterelektronenmikroskopische Aufnahmen gezeigt werden. Da Paclitaxel in 
wässrigen Medien nur sehr schwer löslich ist, kann die Kristallbildung die 
Wasseraufnahme und damit den Polymerabbau maßgeblich beeinflussen. Dazu 
wurden Filme aus PVA-g-PLGA(30) mit einer 5 und 15%igen 
Paclitaxelbeladung hergestellt, und Wasseraufnahme, Massenverlust, sowie 
mögliche Veränderungen des Molekulargewichtes der Filme untersucht. 
Tatsächlich zeigten Filme mit geringerer Beladung eine gesteigerte 
Wasseraufnahme über einen Zeitraum von 12 Tagen. Der Massenabbau verlief 
unabhängig vom Beladungsgrad über 42 Tage linear. Bei 15%iger Beladung 
konnte ein verlangsamter Abbau beobachtet werden. Die Ergebnisse der 
Analyse des Massen- und Molekulargewichtsverlust zeigten, dass der Abbau 
sowohl Merkmale der Oberflächen- als auch der Bulk-Erosion zeigt. 
Elektronenmikroskopische Aufnahmen lieferten einen Eindruck von den 
Veränderungen der Filmmorphologie in Abhängigkeit der Zeit. Zuletzt wurden 
durch ein Air brush-Verfahren die Polymere auf Stents aufgebracht, um mittels 
REM zu untersuchen, ob die Filme nach der Expansion noch intakt blieben. Bis 
auf einige Risse an den mechanisch besonders beanspruchten Stellen der 
Metallglieder, blieb die Matrix unversehrt und haftete weiterhin auf der 
Stentoberfläche. Neben einigen Verunreinigungen konnte auch eine, an 
manchen Stellen ungleichmäßige Beschichtungsdicke beobachtet werden. 
Obwohl die Methode sicherlich noch einiger Optimierungsarbeit bedarf, 
scheinen die verwendeten Polymere zur Herstellung Paclitaxel beladener und 
freisetzender Stents durchaus geeignet zu sein. 
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AUSBLICK 
Nach einer umfangreichen in vitro Charakterisierung Paclitaxel-beladener 
Nanopartikel sind nun weiterführende Studien hinsichtlich ihrer Wirksamkeit in 
einem in-vivo Tiermodell [1] von großem Interesse. Gleichzeitig könnte durch 
die Applikation von Fluoreszenz- (Konfokale Laserscanning Mikroskopie) oder 
radioaktiv-markierten (Autoradiographie) Wirkstoff, die Verteilung im 
arteriellen Gewebe detaillierter analysiert werden. 
 
Bezüglich der Paclitaxel freisetzenden Stents sind zunächst 
Untersuchungen zur Optimierung der Airbrush-Technik notwendig, so dass 
durch gezielte Veränderung von Parametern, wie z.B. Sprühabstand, 
Sprühdauer, Konzentration oder Viskosität der Polymerlösung, die Filmdicke 
auf dem Implantat gesteuert und entsprechend den klinischen Anforderungen 
angepasst werden kann. Die weiterführende Charakterisierung der mechanischen 
Stabilität direkt nach der Stentbeschichtung, aber auch nach der Inkubation mit 
Puffermedien ist genauso unumgänglich, wie die Untersuchung der Frage, ob 
die beschichteten Gefäßprothesen auch sterilisierbar sind, und welche 
Auswirkungen die Sterilisationsmethode auf die Eigenschaften des Polymers 
bezüglich Molekulargewicht, Polydispersität und Freisetzungseigenschaften hat 
[2]. 
Das Potential der Kammpolymere (PVA-g-PLGA) konnte schon in 
früheren Studien verdeutlich werden [13,14]. Die Variabilität der 
Zusammensetzung, die Möglichkeit positive [15] oder negative [16,17] 
Ladungen einzufügen, machen sie auch für die lokale Applikation anderer 
Substanzen interessant, da die Eigenschaften der Polymere an die der Wirkstoffe 
angeglichen werden können. Neben der Anwendung von Paclitaxel, bieten auch 
andere Wirkstoffklassen vielversprechende Ansätze für die 
Restenoseprophylaxe, wie in Tab. 1 zusammengefasst ist.
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Substanz Wirkmechanismus Lit. 
Antiproliferative Substanzen    
Sirolimus  inhibiert Produktion von zur Zellteilung wichtige Poteine, immunsuppressive and antiproliferative Eigenschaften [3] 
Tacrolimus vgl. Sirolimus [4] 
Angiopeptin Somatostasin Analogon; inhibiert viele Zytokine und Wachstumsfaktoren; potentiell antiproliferative Eigenschaften [5] 
Tyrosin kinase 
Inhibitor  
Greift in intrazellulare Zellsignalkaskade ein und reguliert so 
Zellproliferation und -differenzierung [6] 
Antisense Oligonukleotide gegen   
NFκB Hemmung der Aktivierung vieler Cytokine, Wachstumsfaktoren; anti-inflammatorische, antiproliferative Eigenschaften [7] 
E2F decoy  Transkriptionsfaktor; blockiert Aktivierung von Genen, die den Zellzyklus vermitteln; antiproliferative Wirkung [8] 
c-myc Inhibierung des Zellzyklus; antiproliferative Wirkung [9] 
Andere   
VEGF stimuliert die Proliferation der Endothelzellen; verhindert eine verstärkte Neointimabildung [10] 
Saratin inhibiert die vom von-WF-abhängige Thrombozytenadhäsion; verhindert Thrombozytenaggregation, Intimahyperplasie [11] 
Iloprost Prostazyklin Analogon; antithrombotische und  potentiell 
antiproliferative Eigenschaften 
[12] 
Tab. 1: Mögliche Substanzen in der Restenoseprophylaxe zur Einbettung in 
kolloidale Wirkstoffträger oder Stentbschichtungen aus PVA-g-PLGA 
Kammpolyestern. 
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